PMRT1, a *Plasmodium* specific parasite plasma membrane transporter is essential for asexual and sexual blood stage development

Jan Stephan Wichers^{1,2,3}, Paolo Mesén-Ramírez², Jing Yu-Strzelczyk⁴, Gwendolin Fuchs^{1,2,3}, Jan Stäcker², Heidrun von Thien^{1,2}, Arne Alder^{1,2,3}, Isabelle Henshall⁵, Benjamin Liffner⁵, Georg Nagel⁴, Christian Löw^{1,6}, Danny Wilson^{5,7}, Tobias Spielmann², Shiqiang Gao^{4#}, Tim-Wolf Gilberger^{1,2,3,#}, Anna Bachmann^{1,2,3,&}, Jan Strauss^{1,2,3,6,#,&†}

¹Centre for Structural Systems Biology, 22607 Hamburg, Germany.

²Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.

³Biology Department, University of Hamburg, 20146, Hamburg, Germany

⁴Institute of Physiology, Department of Neurophysiology, Biocenter, University of Wuerzburg, 97070 Würzburg, Germany

⁵Research Centre for Infectious Diseases, School of Biological Sciences, University of Adelaide, Adelaide 5005, Australia.

⁶European Molecular Biology Laboratory, Hamburg Unit, Hamburg, Germany

⁷Burnet Institute, 85 Commercial Road, Melbourne 3004, Victoria, Australia.

#Corresponding authors: gao.shiqiang@uni-wuerzburg.de, gilberger@bnitm.de, jan.strauss@geomar.de

&Contributed equally

†Present address: GEOMAR Helmholtz Centre for Ocean Research Kiel, 24105 Kiel, Germany

ORCID:

Jan Stephan Wichers:	0000-0002-0599-1742
Paolo Mesén-Ramírez:	0000-0001-7842-5867
Jing Yu-Strzelczyk:	0000-0002-7576-6831
Gwendolin Fuchs:	0000-0001-9294-6984
Jan Stäcker:	0000-0002-4738-6639
Arne Alder:	0000-0003-4918-4640
Isabelle Henshall:	0000-0002-5906-0687
Benjamin Liffner:	0000-0002-1573-6139
Danny Wilson:	0000-0002-5073-1405
Georg Nagel:	0000-0001-8174-8712
Christian Löw:	0000-0003-0764-7483
Tobias Spielmann:	0000-0002-3968-4601
Shiqiang Gao:	0000-0001-6190-9443
Tim-Wolf Gilberger:	0000-0002-7965-8272
Anna Bachmann:	0000-0001-8397-7308
Jan Strauss:	0000-0002-6208-791X

Abstract

Membrane transport proteins perform crucial roles in cell physiology. The obligate intracellular parasite *Plasmodium falciparum*, an agent of human malaria, relies on membrane transport proteins for the uptake of nutrients from the host, disposal of metabolic waste, exchange of metabolites between organelles and generation and maintenance of transmembrane electrochemical gradients for its growth and replication within human erythrocytes. Despite their importance for *Plasmodium* cellular physiology, the functional roles of a number of membrane transport proteins remain unclear, which is particularly true for orphan membrane transporters that have no or limited sequence homology to transporter proteins in other evolutionary lineages. Therefore, in the current study, we applied endogenous tagging, targeted gene disruption, conditional knockdown and knockout approaches to investigate the subcellular localization and essentiality of six membrane transporters during intraerythrocytic development of *P. falciparum* parasites. They are localized at different subcellular structures – the food vacuole, the apicoplast, and the parasite plasma membrane – and showed essentiality of four out of the six membrane transporters during asexual development. Additionally, the plasma membrane resident transporter 1 (PMRT1, PF3D7_1135300), a unique *Plasmodium*-specific plasma membrane transporter, was shown to be essential for gametocytogenesis. Heterologous expression of wild-type and mutation constructs in *Xenopus laevis* oocytes indicated ion transport upon membrane hyperpolarization and a functional role of negatively charged amino acids protruding into the parasitophorous vacuole lumen. Overall, we reveal the importance of four orphan transporters to blood stage *P. falciparum* development and provide the first functional characterization of *PMRT1*, an essential parasite membrane transporter.

Importance (150 words)

Plasmodium falciparum-infected erythrocytes possess multiple compartments with designated membranes. Transporter proteins embedded in these membranes do not only facilitate movement of nutrients, metabolites and other molecules between these compartments, but are common therapeutic targets and can also confer antimalarial drug resistance. Orphan membrane transporter in *P. falciparum* without sequence homology to transporters in other evolutionary lineages and distant to host transporters may constitute attractive targets for novel intervention approaches. Here, we localized six of these putative transporters at different subcellular compartments and probed into their importance during asexual parasite growth using reverse genetic approaches. In total, only two candidates turned out to be dispensable for the parasite, highlighting four candidates as putative targets for therapeutic interventions. This study reveals the importance of several orphan transporters to blood stage *P. falciparum* development and provides the first functional characterization of *PMRT1*, an essential parasite membrane transporter.

Introduction

Plasmodium spp. malaria parasites inhabit diverse intracellular niches and need to import nutrients and export waste across both, host-cell and parasite membranes. Despite this, there are less than 150 putative membrane transporters encoded in the genome of *Plasmodium falciparum*, the most virulent malaria parasite, making up only 2.5% of all encoded genes (*P. falciparum* 3D7 v3.2: 5280 genes) (1–5), which is reduced compared to other unicellular organisms of similar genome size. The loss of redundant transporters is a typical feature of many intracellular parasites (6) and, as a result, the proportion of transporters that are indispensable for parasite survival increases (2), some of which have been shown to be critical for the uptake of several anti-Plasmodial compounds and/or to be involved in drug resistance (7–20). Moreover, the parasite's intracellular lifestyle resulted in the evolution of additional specialized transporters without human homologues (1). During its intraerythrocytic development, the parasite relies on the uptake of nutrients, such as amino acids, pantothenate or fatty acids, from its host erythrocyte as well as from the extracellular blood plasma (21–24). As *P. falciparum* resides in a parasitophorous vacuole (PV) in the host erythrocyte, nutrients acquired from the extracellular milieu must traverse multiple membranes: the erythrocyte plasma membrane (EPM), the parasitophorous vacuole membrane (PVM), the parasite plasma membrane (PPM) and eventually membranes of intracellular organelles, such as those of the apicoplast or mitochondria (21, 25–27). The unique requirements of malaria parasite survival have led to the evolution of a number of orphan transporters, whose localization or function cannot be predicted based on sequence homology to transporters in other organisms (4, 28). Despite the likely importance of uniquely adapted transporters to *P. falciparum* survival, subcellular localization, essentiality, function and substrate specificity for most *P. falciparum* transporters has not been directly determined (2, 21, 26). The best functional evidence available for many *Plasmodium*-specific transporters comes from a recent knockout screen of these orphan transporters in the rodent malaria parasite *Plasmodium berghei* (28). However, whether observations for different transporters in the *P. berghei* model are directly transferrable to *P. falciparum* have yet to be examined. Therefore, in this study, we explored the localization and essentiality of four predicted orphan transporters that had been partially characterised in *P. berghei* and included two additional transporters with no experimental characterization available.

Results

A subset of orphan transporters characterized in the *P. berghei* malaria model was selected for further characterization in *P. falciparum*. The four transporters selected were reported to be important at different stages of rodent malaria parasite growth with i) *P. berghei* drug/metabolite transporter 2 (*PfDMT2*: PF3D7_0716900) found to be essential for asexual blood stage development, ii) *P. berghei* zinc transporter 1 (*PfZIP1*: PF3D7_0609100) was

essential across transmission stages but not blood stages, where there was only a slight growth defect, iii) *P. berghei* cation diffusion facilitator family protein (*PfCDF*: PF3D7_0715900) knockout parasites had a defect during transmission stages but not during asexual stages, and iv) *P. berghei* major facilitator superfamily domain-containing protein (*PfMFS6*: PF3D7_1440800) was found to be essential for parasite transmission from mosquitos to a new host, with a growth defect observed at asexual and gametocyte stages but not during mosquito stage parasite growth (28, 29). In order to confirm expression of these transporters in *P. falciparum* asexual stages, we screened the list of “Genes coding for transport proteins” included in the Malaria Parasite Metabolic Pathways (MPMP) database (1, 30) for proteins with i) RNA-seq (31, 32) and ii) proteomics evidence (33, 34) for expression in asexual blood stages. We identified two additional putative transporters (PF3D7_0523800, PF3D7_1135300) which had yet to be functionally characterized in the *P. berghei* screen by Kenthirapalan *et al.* (28) or any other experimental model. Both were subsequently included in our characterization of *P. falciparum* orphan transporters, and named as ‘food vacuole resident transporter 1’ (FVRT1: PF3D7_0523800) and as ‘plasma membrane resident transporter 1’ (PMRT1: PF3D7_1135300) based on their subcellular localization. AlphaFold-based structure predictions (35) and results from structure homology search (36) of all six selected transporters are provided in Figure S1.

Localization of putative *P. falciparum* transporters

To determine subcellular localization, we tagged the six putative transporters endogenously with GFP using the selection-linked integration (SLI) system (37) (Figure 1A). Additionally, a glmS ribozyme sequence was included in the 3’UTR, which enabled conditional gene knockdown upon addition of glucosamine (38). Correct integration of the plasmid into the respective genomic locus was verified by PCR and expression of the GFP-fusion protein was confirmed by Western blot for each generated cell line (Figure S2A, B).

All transgenic cell lines expressed the GFP-fusion protein, demonstrating that these transporters are expressed in asexual blood stage parasites (Figure 1B-G, S2A). Expression levels were sufficient to allow determination of subcellular localization (Figure 1B-G): (i) PF3D7_0523800-GFP localized to the food vacuole, (ii) *PfDMT2*-GFP and *PfMFS6*-GFP apicoplast localization, and (iii) *PfZIP1*-GFP and PF3D7_1135300-GFP parasite plasma membrane (PPM) localization. However, *PfCDF*-GFP showed an obscure staining pattern with a weak spot within the parasite cytosol in ring and trophozoite state parasites, but multiple foci in schizont stages (Figure 1D). To pinpoint this localization, an additional cell line with endogenously 3xHA-tagged *PfCDF* was generated, confirming the focal localization of *PfCDF* in asexual stages (Figure S2C).

Except for *PfCDF*, the observed localizations of the other five transporters were confirmed by co-localization studies using appropriate episomally expressed marker proteins: P40PX-

mCherry (39, 40) for the food vacuole, ACP-mCherry (41, 42) for apicoplast and Lyn-mCherry (37, 43) for PPM. The focal distribution of *Pf*CDF-GFP was co-localized with a rhoptry (ARO-mCherry (44, 45)) and a micronemes (AMA1-mCherry (46, 47)) marker, but *Pf*CDF-GFP did not colocalize with either marker (Figure 1H). Additionally, for *Pf*ZIP and PF3D7_1135300 the PPM localization was further confirmed in free merozoites (Figure S2D, E). Accordingly, as noted above, we named PF3D7_0523800 as 'food vacuole resident transporter 1' (FVRT1) and PF3D7_1135300 as 'plasma membrane resident transporter 1' (PMRT1).

Targeted-gene disruption (TGD), conditional knockdown and conditional knockout of putative transporters

In order to test whether the putative transporters are essential for *P. falciparum* during its intraerythrocytic cycle, we first tried to functionally inactivate them by targeted gene disruption (TGD) using the SLI system (37) (Figure S3A). TGD cell lines were successfully obtained for *Pf*ZIP1 and *Pf*CDF (Figure S3B, C). For *Pf*ZIP1-TGD, the correct integration of the plasmid into the genomic locus and absence of wildtype locus was verified by PCR and subsequent growth experiments revealed no growth defect compared to *P. falciparum* 3D7 wildtype parasites (Figure S2B), suggesting its redundancy during asexual parasite proliferation. For *Pf*CDF-TGD the correct integration of the plasmid into the genomic locus was also verified, but wildtype DNA was still detectable and remained even upon prolonged culturing under G418/WR selection and limited dilution cloning (Figure S3C). In contrast, six (*Pf*PMRT1, *Pf*DMT2) or eight (*Pf*FVRT1, *Pf*MFS6) independent attempts to obtain TGD cell lines for the other four transporters with the respective plasmids failed, indicating that these genes have an indispensable role in blood stage parasite growth.

To probe into the function of the putative transporters where we were unable to generate gene-knockout parasites, we utilized the glmS ribozyme sequence. The corresponding sequence was integrated into the 3'UTR of the targeted genes. This enabled the induction of conditional degradation of respective mRNAs upon addition of glucosamine (38) and the assessment of the phenotypic consequences. Upon addition of 2.5 mM glucosamine to young ring stage parasites we found a 76.8% (+/- SD 3.7) reduction in GFP fluorescence intensity in *Pf*DMT2-GFP parasites, 72.7% (+/- SD 9.4) reduction in *Pf*MFS6-GFP and a 77.7% (+/- SD 6.1) reduction in *Pf*PMRT1-GFP in schizonts of the same cycle (Figure 2A–C, S4A–C). No measurable reduction in fluorescence intensity could be detected for *Pf*FVRT1-GFP or *Pf*CDF-GFP expressing parasite lines (Figure S4D–F). For parasite cell lines with a significant reduction in the expression of the endogenously tagged protein, proliferation was analyzed in the absence and presence of 2.5 mM glucosamine (Figure 2D, S4G). While no significant effect on growth was observed for *Pf*MFS6 and *Pf*PMRT1, a growth reduction of 68.5 % (+/- SD 2.1) over two cycles was observed upon knockdown of *Pf*DMT2. For *Pf*PMRT1, a minor growth delay was measurable, which resulted in a reduced parasitemia at day 3 upon knockdown

using both, 2.5 mM or 5 mM glucosamine (Figure 2E), and fewer newly formed ring stage parasites at 84 hours post invasion (hpi) (Figure 2F) were observed.

To better characterize the minor growth phenotype of *PfPMRT1*-GFP-*glmS* parasites that might be due to incomplete knockdown, we generated a conditional *PfPMRT1* knockout cell line (*condΔPMRT1*) using the Dimerizable Cre (DiCre) system (48, 49). Again using the SLI system (37), the endogenous *PfPMRT1* was disrupted upstream of the region encoding the N-terminal transmembrane domain, but, at the same time introducing a recodonized second functional copy of *PfPMRT1* flanked by loxP sites in the genomic locus. This loxP-flanked allelic copy of *PfPMRT1* encodes an additional 3x hemagglutinin (HA) tag, which can be conditionally excised upon addition of a rapamycin analog (rapalog) via the enzymatic activity of an episomally expressed DiCre (Figure 3A). First, correct integration of the plasmid into the genomic locus was verified by PCR (Figure 3B). Second, expression and localization of the recodonized HA-tagged protein at the PPM was verified by colocalization with the merozoite plasma membrane marker MSP1 (50) (Figure 3C). Third, excision of the recodonized gene upon rapalog addition was confirmed on genomic level by PCR (Figure 3D) and on protein level by Western blot analysis at 24 hpi and 48 hpi (Figure 3E). To assess the effect of conditional *PfPMRT1* knockout on parasite proliferation, we determined growth of the transgenic parasite cell line with and without rapalog over five days (Figure 3F, S5A). In contrast to the *glmS*-based knockdown experiment, DiCre-based gene excision (induced by the addition of rapalog to young ring stages of *condΔPMRT1* parasite cell cultures) abolished growth within the first replication cycle (Figure 3F, S5A). The specificity of the observed growth phenotype was verified by gene complementation. To achieve this, we episomally expressed recodonized *PfPMRT1* with TY1-epitope tag either under the constitutive *nmd3* or the weaker *sf3a2* promoter (51) in the *condΔPMRT1* cell line (Figure 3D, F, S5B, C). Correct localization of the TY1-tagged *PfPMRT1* at the PPM was verified by immunofluorescence assays (IFA) (Figure 3G). Notably both, complementation of the *PfPMRT1* knockout cell line (*condΔPMRT1*) with recodonized *PfPMRT1* either under control of the constitutive *nmd3* or the weaker *sf3a2* promoter, restored parasite growth (Figure 3F, S5B, C). The level of growth restoration with low level expression of recodonized *PfPMRT1* is in line with the results from *glmS*-knockdown experiments, which showed that a reduction of about 75% in protein expression resulted only in a minor growth perturbation (Figure 2C, D).

Loss of the PPM-localized *PfPMRT1* leads to an arrest of parasite development at trophozoite stage and the formation of vacuoles

To determine, which particular parasite stages are affected by the knockout of *PfPMRT1*, we added rapalog to tightly synchronized parasites at different time points (4, 20 and 32 hpi) (Figure 4A) and monitored parasite growth by flow cytometry. Additionally, we quantified growth perturbation by microscopy of Giemsa smears at 4, 20, 24, 32, 40, 48, 72 and 96 hpi

(Figure 4B, S6A, B). When adding rapalog at 4 hpi, parasite development progressed through ring and early trophozoite stages up to 24 hpi with no visible abnormality. Afterwards, parasites with deformed and enlarged vacuoles started to appear and further development occurred to be stalled. At 32 hpi, almost all parasites had developed to late trophozoites/early schizonts in the control, whereas these stages were completely absent in *PfPMRT1*-deficient parasites. Over 50% of the parasites were pycnotic or possessed large vacuoles, the remaining parasites stayed arrested at the trophozoite stage. Quantification of the percentage of parasites with vacuoles between 20 hpi and 32 hpi revealed 94.8% (+/- SD 4.0) vacuole-positive parasites (Figure 4C). The activation of gene excision at later time points by adding rapalog at 20 hpi or 32 hpi resulted in no or minor growth perturbation in the first cycle with successful re-invasion, but again led to parasites arresting at the trophozoite stage in the second cycle with an accumulation of vacuoles (Figure 4A, S6A, B).

In order to get further insights into the morphological changes in *PfPMRT1*-deficient parasites with its vacuolization, we incubated these parasites with dihydroethidium (DHE) to visualize the parasite cytosol (40). We observed an absence of staining in the vacuoles, suggesting they are not filled with parasite cytosol (Figure 4D). Next, we transfected the *condΔPMRT1* cell line with a plasmid encoding the PPM marker Lyn-mCherry (37) and observed Lyn-mCherry-positive vacuoles upon knockout of *PfPMRT1* starting to become visible at 24 hpi, indicating that the vacuoles originate from the PPM (Figure 4E). In line with this, vacuole membranes were also stainable with BODIPY TR C5 ceramide in *condΔPMRT1* parasites at 32 hpi (Figure 4F).

Depletion of *PfPMRT1* results in an early arrest of gametocyte development

RNA-seq data suggest *PfPMRT1* is also expressed during other developmental stages, such as gametocytes (52, 53). Therefore, we assessed expression of *PfPMRT1*-GFP during gametocytogenesis by re-engineering *PfPMRT1*-GFP-*glmS* in the inducible gametocyte producer (iGP) '3D7-iGP (55)' parasite line, which allows the robust induction of sexual commitment by conditional expression of gametocyte development 1 protein (GDV1) upon addition of shield-1 (55) (Figure S7A). We show that *PfPMRT1* is indeed expressed during all stages of gametocytogenesis and again localizes to the PPM, colocalizing with the PPM-marker Lyn-mCherry (37) (Figure 5A, B). Conditional knockdown of *PfPMRT1* via the *glmS*-ribozyme system (Figure S7B) resulted in a reduction in *PfPMRT1*-GFP fluorescence intensity of 79.4% (+/- SD 9.2%) at 7 days post induction (dpi) or 75.5% (+/- SD 23.2%) at 10 dpi, without an effect on gametocyte development (Figure S7C–F). In order to exclude that a role of *PfPMRT1* in gametocytogenesis is covered by only a partial knockdown resulting in low levels of expressed protein and to determine if *PfPMRT1* is essential for gametocytogenesis, we episomally expressed GDV1-GFP-DD in the *condΔPMRT1* parasite line, enabling conditional induction of sexual commitment upon addition of shield 1 in these parasites (56). Conditional

knockout of *PfPMRT1* in these transgenic parasites at day three post gametocyte induction resulted in pycnotic parasites from day 5 onwards, while excision of *PfPMRT1* at day 5 post induction had no effect on gametocyte development (Figure 5C, D). Excision of the recodonized gene upon rapalog addition was confirmed at a genomic level by PCR for both conditions (Figure 5E). Quantification of parasite stages at day 10 post induction of GDV1 expression revealed 77.9% (+/- SD 7.7%) gametocytes and 22.1% (+/- SD 7.7%) pycnotic parasites in the control, while 100% of parasites were already pycnotic in the cultures, with induced knockout by addition of rapalog at day 3 post gametocyte induction by GDV1 expression (Figure 5F). This data indicates that *PfPMRT1* is important for early gametocyte development.

PMRT1 is unique to the genus *Plasmodium* and interspecies complementation assays showed partial functional conservation

PfPMRT1 shows a lack of sequence similarities with known or putative transporters and/or conserved domains shared with known transporter families (2, 5). Our phylogenetic analysis revealed that homologs of *PfPMRT1* are present across *Plasmodium* species with amino acid sequence identities of about 90% in the subgenus *Laverania*, but about 50% outside *Laverania* (Figure 6A). However, prediction of the protein structure using AlphaFold (35) indicates two bundles of four transmembrane helices with reasonable similarity of the C-terminal bundle with the photosynthetic reaction center Maquette-3 protein (57) (RMSD of 3.12) (Figure 6B, Figure S1B). In order to test for functional conservation, we expressed the *PfPMRT1* homologs of *P. vivax* (PVP01_0936100) and *P. knowlesi* (PKNH_0933400) episomally as C-terminal Ty-1 fusion proteins under the *nmd3* promoter in the cond Δ PMRT1 parasites. Both protein variants localized correctly at the PPM, as shown by IFA (Figure 6C), and were able to partially restore growth after two cycles to 64.8% (+/- SD 9.8%) and 65.1% (+/- SD 7.4%) compared to the control (Figure 6D, S8). Excision of the recodonized endogenous *Pfpmrt1* gene upon rapalog addition was confirmed at a genomic level by PCR (Figure 6E). These data indicate that PMRT1 is functionally conserved within the genus *Plasmodium*.

Functional characterization of *PfPMRT1* in *Xenopus* oocytes revealed hyperpolarization-activated ion transport activity

PfPMRT1 encodes a 410 amino acid protein with eight predicted (58) transmembrane domains (TM) (Figure S1). The N- and C-terminal parts of *PfPMRT1* are both predicted (59) to be facing the cytosolic side of the parasite. Surface electrostatics indicate a clear polarity of *PfPMRT1* with negative charges facing the parasitophorous vacuole (PV) lumen and positive charges inside the parasite cytosol (Figure 7A). The loops protruding into the PV lumen of *PfPMRT1* are generally larger than the cytosolic loops and possess several negatively charged amino acids, especially the first loop between TM1 and TM2 with 10 negatively charged amino acids.

In contrast, the loop between TM4 and TM5 on the parasite cytosol (PC) side contains six positively charged amino acids. These two stretches of charged amino acids were hypothesized to be important for protein function and were replaced with neutral amino acids to test this hypothesis (Figure 7B). Full-length, WT *PfPMRT1* as well as the two mutants (MutPV, with sequence **EDDIDEYNIKGNEEE** modified to **QNAIAQYNIKGNAAA**; MutPC, with sequence **KIEKHFRKKF** modified to **AIQAAFAMAF**), each as C-terminal eYFP fusion proteins, were expressed in *Xenopus laevis* oocytes in order to characterize its function (Figure 7D). The *PfPMRT1*-WT expressing oocytes showed significant inward currents when clamped at -160 mV, indicating a hyperpolarization-activated ion transport (Figure 7C). The current of MutPV-expressing oocytes was significantly reduced compared to *PfPMRT1*-WT ($W = 10$, $n_1 = 10$, $n_2 = 7$, $P = 0.0147$, two tailed Wilcoxon rank sum test), while in MutPC-expressing oocytes the observed current was only slightly smaller than in WT controls (Figure 7D, E), suggesting that the negatively charged amino acids of the first loop protruding into the PV lumen are important for the function of *PfPMRT1*. To translate these results to the parasite, we expressed *PfPMRT1*-WT and the two sequence mutants as C-terminal Ty-1 fusion complementation constructs under the *nmd3* promoter in *condΔPfPMRT1* parasites. These experiments showed, that *PfPMRT1*-MutPC was able to completely restore parasite growth, while *PfPMRT1*-MutPV showed only 59.2% (SD +/- 9.5) growth compared to the control after two developmental cycles (Figure 7F, G, S9 A–C). These data support the functional role of the negatively charged amino acids of the first loop protruding into the parasitophorous vacuole lumen for transport activity during the intraerythrocytic developmental cycle of the parasite.

Discussion

To date, the predicted ‘transportome’ of *P. falciparum* consists of 117 putative transport systems (encoded by 144 genes) classified as channels ($n=19$), carriers ($n=69$), and pumps ($n=29$) (2). Functions of the vast majority of transporter genes were inferred from sequence homology to model organisms, however, given their lack of homology, 39 gene products could not be associated with any functional or subcellular localization and were categorized as orphan transporters accordingly (4). Here, we concentrated on four candidates from the orphan group, which were already partially characterized in *P. berghei*, and included two additional so far uncharacterized putative transporter proteins.

We localized *PfFVRT1*-GFP – annotated on PlasmoDB (60) as putative divalent metal transporter – at the food vacuole of the parasite, which is in line with a previously predicted food vacuole association (1) and its reported homology (1, 61) to the conserved eukaryotic endosomal/lysosomal natural resistance-associated macrophage protein (NRAMP) transporter (62) in our structure similarity search. Repeated attempts to generate a TGD cell line failed, indicating an important role of this transporter during asexual blood stage

development which is in agreement with data from a *P. falciparum* genome wide essentiality screen (63).

In concordance with recently published data identifying *PbDMT2* and *PbMFS6* as leaderless apicoplast transporters (29), we localized GFP-fusion proteins of *PfDMT2* and *PfMFS6* at the apicoplast. Successful knockdown of *PfDMT2* resulted in a growth defect in the second cycle after induction, resembling the described delayed death phenotype of other apicoplast genes that were functionally inactivated (29, 64–66). It suggests an essential role of *PfDMT2* in apicoplast physiology, as observed by Sayers *et al.* (29) for the rodent malaria *P. berghei*. This is further supported by our failed attempts to disrupt this gene using the SLI system.

We also failed to disrupt the *PfMFS6* locus, which is in agreement with the gene knockout studies in *P. berghei* that led to a markedly decreased multiplication rate (28, 29, 67). Nevertheless, glmS-based knock-down, although comparable to *PfDMT2*-GFP knockdown (72.7% versus 76.8% reduction in GFP fluorescence, respectively) had no effect on parasite proliferation in our study. This might indicate that these reduced levels of *PfMFS6*, in contrast to reduced levels of *PfDMT2*, are sufficient for normal asexual replication *in vitro*.

Another candidate, *PfCDF*, annotated as putative cation diffusion facilitator family protein, showed multiple cytosolic foci within the parasite with no co-localization with apical organelle markers. The homologue in *Toxoplasma gondii*, *TgZnT* (TgGT1_251630) shows a similar cellular distribution (68). It has recently been shown to transport Zn^{2+} , to localize to vesicles at the plant-like vacuole in extracellular tachyzoites and to be present at dispersed vesicles throughout the cytoplasm of intracellular tachyzoites (68). Our data suggests that *PfCDF* is not essential for parasite *in vitro* blood stage development even though we were not able to generate a clonal wild-type free TGD cell line. Its redundancy is further supported by published data, showing that CDF proteins are non-essential for *in vivo* blood stage development in *P. yoelli* (69) and *P. berghei* (28, 67) and by its high (1.0) mutagenesis index score in a *P. falciparum* genome-wide mutagenesis screen (63).

Finally, two putative transporters, *PfZIP1* and *PfPMRT1*, localized to the PPM. We show that *PfZIP1* is non-essential for *P. falciparum* *in vitro* blood stage development, in line with a high (0.7) mutagenesis index score in a *P. falciparum* genome-wide mutagenesis screen (63). However, this is in contrast to the reported strong fitness loss in *P. berghei* (67) knockout mutants and failed knockout attempts in *P. yoelli* and *P. berghei* *in vivo* mouse models (29, 69). These observations may reflect differences between *Plasmodium* species or differing requirements for *in vitro* and *in vivo* growth conditions.

PfPMRT1 is annotated as a conserved *Plasmodium* membrane protein with unknown function. It has been described as a protein showing structural characteristics of a transporter, without sharing sequence similarities with known or putative transporters and/or conserved domains of known transporter families (2, 5). Our phylogenetic analysis confirmed PMRT1 as unique

for *Plasmodium* species with high sequence conservation only within the *Laverania* subgenus (70). In line with data from genome-wide mutagenesis screens (63, 67) and reported failed knockout attempts in *P. yoelli* (69), we found that *PfPMRT1* is essential for parasite growth, as its functional inactivation resulted in growth arrest at the trophozoite stage accompanied by the accumulation of PPM-derived vacuoles within the parasite. In contrast, conditional knockdown resulted only in a growth delay, indicating that minor residual *PfPMRT1* protein levels appear to be sufficient to promote parasite growth. This finding was validated by episomal expression of an allelic copy under the control of the weak *sf3a2* promoter (51) in the *PfPMRT1* knockout parasites. Additionally, we found that *PfPMRT1* is essential for early gametocytogenesis. Interestingly, the induction of the knockout at stage II–III had no effect on gametocytogenesis. This might be due to sufficient amounts of *PfPMRT1* already present at the PPM, but could also indicate that the function of the transporter is not required for later stage gametocyte maturation.

The *PfPMRT1*-WT-expressing *Xenopus* oocytes showed a hyperpolarization-activated ion transport activity, which is reduced in the variant featuring mutations in the first loop that extends into the parasitophorous vacuole. But it remains to be determined whether the hyperpolarization-activated ion transporting activity is the main physiological function of *PfPMRT1*. Additional functions such as transporting of other molecules, or cooperative interaction with other parasite proteins might play a role under physiological conditions. However, the mutation analysis suggested that the negatively charged amino acids of the first loop protruding into the PV lumen are important for the function of *PfPMRT1*. Interestingly, AlphaFold predicts smaller helical structures within this negatively charged loop, which possibly function as flexible gates and/or could be involved substrate binding.

For future work, further functional and pharmacological characterization of this transporter will provide insights into its biological role in different stages of the parasites life cycle, as transcriptomic data indicates – along with expression in blood stages (31, 32) – *PfPMRT1* is expressed in oocysts of *P. falciparum* (54, 71) and *P. berghei* (72).

Material and methods

Cloning of plasmid constructs for parasite transfection

For endogenous tagging using the SLI system (37) a 889 bp (for *PfPMRT1*; PF3D7_1135300), 905 bp (*PfFVRT1*; PF3D7_0523800), 827bp (*PfZIP1*; PF3D7_0609100), 873 bp (*PfDMT2*; PF3D7_0716900), 877 bp (*PfMFS6*; PF3D7_1440800), 785 bp (*PfCDF*; PF3D7_0715900) long homology region (HR) was amplified using 3D7 gDNA and cloned into pSLI-GFP-glmS (73) (derived from pSLI-GFP (37)) using the NotI/MluI restriction site. In order to generate

409 *PfPMRT1*-2xFKBP-GFP a 1000 bp long HR was amplified using 3D7 gDNA and cloned into
 410 pSLI-2xFKBP-GFP (37).

411 For SLI-based targeted gene disruption (SLI-TGD) (37) a 501 bp (*PfPMRT1*), 378 bp
 412 (*PfFVRT1*), 511 bp (*PfZIP1*), 399 bp (*PfDMT2*), 396 bp (*PfMFS6*), 741 bp (*PfCDF*) long
 413 homology region was amplified using 3D7 gDNA and cloned into the pSLI-TGD plasmid (37)
 414 using NotI and MluI restriction sites.

415 For conditional deletion of *PfPMRT1*, the first 492 bp of the *PfPMRT1* gene were PCR amplified
 416 to append a first loxP site and a recodonized T2A skip peptide. The recodonized full-length
 417 coding region of *PfPMRT1* was synthesized (GenScript, Piscataway, NJ, USA) and PCR
 418 amplified with primers to add a second loxP site after the gene to obtain a second fragment.
 419 Both fragments were cloned into pSLI-3xHA (51), using NotI/SpeI and AvrII/XmaI sites. This
 420 resulted in plasmid pSLI-*PfPMRT1*-loxP and the resulting transgenic cell line after successful
 421 genomic modification was transfected with pSkip-Flox (37) using 2 µg/ml Blasticidin S to obtain
 422 a line expressing the DiCre fragments (cond Δ PMRT1).

423 For complementation constructs, the recodonized *PfPMRT1* gene was PCR amplified using
 424 primers to append the TY1 sequence and cloned via XhoI and AvrII or KpnI into pEXP1comp
 425 (51) containing yDHODH as a resistance marker and different promoters (*nmd3*
 426 (PF3D7_0729300), *sf3a2* (PF3D7_0619900)) driving expression of the expression cassette.
 427 This resulted in plasmids c-*nmdr**PfPMRT1*-ty1 and c-*sf3a2**PfPMRT1*-ty1.

428 *PfPMRT1* homologues of *P. vivax* (PVP01_0936100) (74) and *P. knowlesi* (PKNH_0933400)
 429 (75) were amplified from parasite gDNA and cloned into p^{*nmd3*}EXP1comp (51) via the XhoI/AvrII
 430 restriction site. For co-localization experiments the plasmids pLyn-FRB-mCherry (37), P40PX-
 431 mCherry (40), pARL-*crt*ACP-mCherry (42), pARL-*ama1*ARO-mCherry (44) and pARL-*ama1*AMA1-
 432 mCherry (47) were used. For conditional gametocyte induction yDHODH was amplified by
 433 PCR from pARL-*ama1*AMA1-mCherry-yDHODH (47) and cloned into GDV1-GFP-DD-
 434 hDHFR(56)(56) using the XhoI/XhoI restriction site. For expression in *Xenopus* oocysts
 435 *PfPMRT1* was amplified from c-*nmdr**PfPMRT1*-ty1 and DNA fragments were ligated and
 436 inserted into the oocyte expression vector pGEM-HE (76), containing a C-terminal eYFP using
 437 the BamHI/XhoI restriction site. As a control of plasma membrane-targeted channel protein,
 438 the cyclic nucleotide-gated potassium channel SthK (77) was also cloned into the pGEM-
 439 HE vector with C-terminal eYFP using the BamHI/XhoI restriction site.

440 The pGEM-HE plasmids containing SthK, *PfPMRT1* or the mutant were linearized by NheI
 441 digestion before the RNA generation. Mutations were made by QuikChange Site-Directed
 442 Mutagenesis. The complementary RNA (cRNA) was synthesized by in vitro transcription using
 443 the AmpliCap-MaxT7 High Yield Message Maker Kit (Epicentre).

444 Sequences of the MutPC and MutPV variants were amplified from pGEM plasmid constructs
 445 and cloned into c-*nmd3**PfPMRT1*-ty1 using the XhoI/AvrII restriction site.

Oligonucleotides and plasmids used in this study are listed in Table S1A and S1B.

***P. falciparum* culture and transfection**

Blood stages of *P. falciparum* 3D7 were cultured in human erythrocytes (O+). Cultures were maintained at 37°C in an atmosphere of 1% O₂, 5% CO₂ and 94% N₂ using RPMI complete medium containing 0.5% Albumax according to standard protocols (78). To maintain synchronized parasites, cultures were treated with 5% sorbitol (79).

Induction of gametocytogenesis was done as previously described (55, 56). Briefly, GDV1-GFP-DD expression was achieved by addition of 4 µM shield-1 to the culture medium and gametocyte cultures were treated with 50 mM N-acetyl-D-glucosamine (GlcNAc) for five days starting 72 hours post shield-1 addition to eliminate asexual parasites(80). Alternatively, asexual ring stage cultures with >10% parasitemia were synchronized with Sorbitol (79) cultured for 24 hours and treated with 50 mM N-acetyl-D-glucosamine (GlcNAc) (80) for five days.

For transfection, Percoll-purified (81) late-schizont-stage parasites were transfected with 50 µg of plasmid DNA using Amaxa Nucleofector 2b (Lonza, Switzerland) as previously described(82). Transfectants were selected either using 4 nM WR99210 (Jacobus Pharmaceuticals), 2 µg/ml Blasticidin S (Life Technologies, USA), or 0.9 µM DSM1 (83) (BEI Resources; <https://www.beiresources.org>). In order to select for parasites carrying the genomic modification using the SLI system (37), G418 (Sigma-Aldrich, St. Louis, MO) at a final concentration of 400 µg/ml was added to 5% parasitemia culture. The selection process and testing for integration were performed as previously described (37).

For SLI-TGD, a total of six (*PfPMRT1*, *PfDMT2*, *PfZIP1*, *PfCDF*) or eight (*PfFVRT1*, *PfMFS6*) independent 5 ml cultures containing the episomal plasmid were selected under G418 for at least eight weeks.

Imaging and immunofluorescence analysis (IFA)

Images of *Xenopus* oocysts were taken 3 days after injection using a Carl Zeiss LSM 5 Pascal Laser Scanning Confocal Microscope, with a 40x/0.8 water immersion objective. The eYFP fluorescence was excited at 514 nm of the Argon laser and obtained at 530 - 600 nm.

Fluorescence images of infected erythrocytes were observed and captured using a Zeiss Axioskop 2plus microscope with a Hamamatsu Digital camera (Model C4742-95), a Leica D6B fluorescence microscope equipped with a Leica DFC9000 GT camera and a Leica Plan Achromat 100x/1.4 oil objective or an Olympus FV3000 with a x100 MPLAPON oil objective (NA 1.4).

Microscopy of unfixed IEs was performed as previously described (84). Briefly, parasites were incubated in RPMI1640 culture medium with Hoechst-33342 (Invitrogen) for 15 minutes at 37°C prior to imaging. 7 µl of IEs were added on a glass slide and covered with a cover slip.

BODIPY TR C5 ceramide (Invitrogen) staining was performed by adding the dye to 32 hours post invasion parasites in a final concentration of 2.5 μ M in RPMI as previously described (84). For DHE staining of the parasite cytosol (40), 80 μ l of resuspended parasite culture were incubated with DHE at a final concentration of 4.5 μ g/ml in the dark for 15 minutes prior to imaging.

IFAs were performed as described previously (85). Briefly, IEs were smeared on slides and air-dried. Cells were fixed in 100% ice cold methanol for 3 minutes at -20°C. Afterwards, cells were blocked with 5% milk powder for 30 minutes. Next primary antibodies were diluted in PBS/3% milk powder and incubated for 2 hours, followed by three washing steps in PBS. Secondary antibodies were applied for 2 hours in PBS/3% milk powder containing 1 μ g/ml Hoechst-33342 (Invitrogen) or DAPI (Roche) for nuclei staining, followed by 3 washes with PBS. One drop of mounting medium (Mowiol 4-88 (Calbiochem)) was added and the slide sealed with a coverslip for imaging.

To assess the localisation of the endogenously HA-tagged *Pf*PMRT1 IFAs were performed in suspension with Compound 2-stalled schizonts (86) to distinguish protein located at the PPM from that located at the PVM as previously done (51, 87). For this, trophozoite stages were treated with Compound 2 (1 μ M) overnight, and arrested schizonts were harvested, washed in PBS, and fixed with 4% paraformaldehyde/0.0075% glutaraldehyde in PBS. Cells were permeabilized with 0.5% Triton X-100 in PBS, blocked with 3% BSA in PBS, and incubated overnight with primary antibodies diluted in 3% BSA in PBS. Cells were washed 3 times with PBS and incubated for 1 hour with Alexa 488 nm or Alexa 594 nm conjugated secondary antibodies specific for human and rat IgG (Invitrogen) diluted 1:2,000 in 3% BSA in PBS and containing 1 μ g/ml DAPI. Cells were directly imaged after washing 5 times with PBS

Antisera used: 1:200 mouse anti-GFP clones 7.1 and 13.1 (Roche), 1:500 rat anti-HA clone 3F10 (Roche), 1:1000 human anti-MSP1 (88), 1:10000 mouse anti-TY1 (ThermoFischer Scientific Cat.No: MA5-23513). Contrast and intensities were linear adjusted if necessary and cropped images were assembled as panels using Fiji (89), Corel Photo-Paint X6 and Adobe Photoshop CC 2021.

Immunoblots

Immunoblots were performed using saponin lysed infected erythrocytes. Parasite proteins were separated on a 10% SDS-PAGE gel using standard procedures and transferred to a nitrocellulose membrane (AmershamTMProtranTM 0.45 μ m NC, GE Healthcare) using a transblot device (Bio-Rad) according to manufacturer's instructions.

Rabbit anti-aldolase (90) and anti-sbp1 (90) antibodies were diluted 1:2,000, mouse anti-GFP clones 7.1 and 13.1 (Roche) antibody was diluted 1:500 or 1:1,000 and rat anti-HA clone 3F10 (Roche) antibody was diluted 1:1,000.

The chemiluminescent signal of the HRP-coupled secondary antibodies (Dianova) was visualized using a Chemi Doc XRS imaging system (Bio-Rad) and processed with Image Lab Software 5.2 (Bio-Rad). To perform loading controls and ensure equal loading of parasite material anti-aldolase antibodies were used. The corresponding immunoblots were incubated two times in stripping buffer (0.2 M glycine, 50 mM DTT, 0.05% Tween 20) at 55°C for 1 hour and washed 3 times with TBS for 10 minutes.

Growth Assay

A flow cytometry-based assay adapted from previously published assays (40, 91) was performed. For this, parasite cultures were resuspended and 20 µl samples were transferred to an Eppendorf tube. 80 µl RPMI containing Hoechst-33342 and dihydroethidium (DHE) was added to obtain final concentrations of 5 µg/ml and 4.5 µg/ml, respectively. Samples were incubated for 20 minutes (protected from UV light) at room temperature, and parasitemia was determined using an LSRII flow cytometer by counting 100,000 events using the FACSDiva software (BD Biosciences) or using an ACEA NovoCyt flow cytometer.

Stage distribution assay

In order to obtain tightly synchronized parasite cultures, percoll purified schizonts(81) were cultured for four hours together with fresh erythrocytes, followed by sorbitol synchronization and resulting in a four-hour age window of parasites. Next, the culture was divided in four dishes and rapalog was added at a final concentration of 250 nM immediately to one dish and at 20 hours post invasion (hpi) and 32 hpi to the respective dishes. Giemsa smears and samples for flow cytometry were collected at the indicated timepoints. The parasitemia was determined using a flow cytometry assay and the stages were determined microscopically counting at least 50 infected erythrocytes per sample and timepoint.

Gametocyte stage distribution assay

Giemsa-stained blood smears 10 days post induction of GDV1 expression were obtained and at least 10 fields of view were recorded using a 63x objective per treatment and time point. Erythrocyte numbers were then determined using the automated Parasitemia software (<http://www.gburri.org/parasitemia/>) while the number of gametocytes, pycnotic and asexual parasites was determined manually in >1800 erythrocytes per sample. This assay was done blinded.

GlmS-based knockdown

GlmS based knockdown assay was adapted from previously published assays (38, 73). To induce knockdown 2.5 or 5 mM glucosamine was added to highly synchronous early rings stage parasites. As a control, the same amount of glucosamine was also added to 3D7 wildtype

parasites. For all analyses, the growth medium was changed daily, and fresh glucosamine were added every day.

Knockdown was quantified by fluorescence live cell microscopy at day 1 and 3 of the growth assay. Parasites with similar size were imaged, and fluorescence was captured with the same acquisition settings to obtain comparable measurements of the fluorescence intensity. Fluorescence intensity (integrated density) was measured with Fiji(89), and background was subtracted in each image. The data were analyzed with Graph Pad Prism version 8.

GlmS based knockdown experiments in gametocytes were performed as described previously (92). Briefly, synchronized ring stage cultures were induced by the addition of shield-1. At day 3 post induction the culture was spilt into two dishes and one dish was cultured in the presence of 2.5 mM glucosamine for the remaining ten days. Knockdown was quantified by fluorescence live cell microscopy at day 7 and 10 post induction, as described above and gametocyte parasitemia was determined at day 10 post induction using the automated Parasitemia software (<http://www.gburri.org/parasitemia/>).

DiCre mediated conditional knockout

The parasites containing the integrated pSLI-*PfPMRT1-loxP* construct were transfected with pSkip-Flox (37) using 2 µg/ml Blasticidin S to obtain a line expressing the DiCre fragments. To induce excision, the tightly synchronized parasites (detailed description see growth assay) were split into 2 dishes and rapalog was added to one dish (Clontech, Mountain View, CA) to a final concentration of 250 nM. The untreated dish served as control culture. Excision was verified at genomic level after 24 and 48 hours of cultivation by PCR and on protein level by Western blot using anti-HA antibodies.

Phylogenetic analysis

A blastp search of the PMRT1 sequence (PlasmoDB (60): PF3D7_1135300; UniProt: Q8II12) was performed against the nr database (9 May 2021) using Geneious Prime 2021.2.2 (<https://www.geneious.com>) and an E-value of 10e-0 (BLOSUM62 substitution matrix). Blast hits were filtered for sequences from taxa represented in the currently favored haemosporidian parasite phylogeny (93). The phylogeny derived from an amino acid alignment using Bayesian framework with a partitioned supermatrix and a relaxed molecular clock (18_amino_acid_partitioned_BEAST_relaxed_clock_no_outgroup.tre; (93)) was visualized with associated data using the R package ggtree v3.3.0.900 (94, 95). A multiple protein sequence alignment of PMRT1 and homologous sequences was performed using MAFFT v7.490 (96) using the G-INS-I algorithm to obtain a highly accurate alignment. Protein statistics were calculated using Geneious Prime 2021.2.2 (<https://www.geneious.com>) and EMBOSS pepstats v6.6.0.0 (97).

Prediction of protein structures

AlphaFold structure predictions (35) were retrieved from <https://alphafold.ebi.ac.uk> and the PDB used for DALI protein structure homology search (36). PyMOL Molecular Graphics System, Version 2.5.2 Schrödinger was used for visualization of all structures, generation of figures and the calculation of the root mean square deviation (RMSD) between the predicted crystal structure of *PfPMRT1* and the Maquette-3 protein (PDB: 5vjt (57)) by cealign. The Adaptive Poisson-Boltzmann Solver (APBS) within PyMOL was used to predict the surface electrostatics of *PfPMRT1*.

Electrophysiology experiments

Stage V and VI oocytes were surgically removed from female *Xenopus laevis* by immersion in water containing 1 g/L Tricain and isolated from theca and follicle layers by digestion with 0.14 mg ml⁻¹ collagenase I. Oocytes were injected with 20 ng cRNA and were incubated at 16°C for 3 days in ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, 10 mM HEPES, pH7.4). Electrophysiological measurements with *Xenopus* oocytes were performed at room temperature (20–23°C) with a two-electrode voltage clamp amplifier (TURBO TEC-03X, npa electronic GmbH, Tamm, Germany). The bath solutions for electrophysiological recording are indicated in each figure legend. Electrode capillaries ($\Phi=1.5$ 99 mm, Wall thickness 0.178 mm, Hilgenberg) were filled with 3 M KCl, with tip openings of 0.4–1 M Ω . USB-6221 DAQ device (National Instruments) and WinWCP (v5.5.3, Strathclyde University, UK) are used for data acquisition. Origin2020 Pro and the R software environment (98) were used for data analysis. Data was visualized in R using ggplot2 (99) and patchwork (100).

Parasite icons were generated using BioRender (biorender.com) and statistical analysis was performed using GraphPad Prism version 8 (GraphPad Software, USA).

Acknowledgements

We thank Michael Filarsky for providing the pHcamGDV1-GFP-DD_hDHFR plasmid, Egbert Tannich for providing *P. vivax* and *P. knowlesi* gDNA, Mike Blackman for the anti-MSP1 antibody, Jacobus Pharmaceuticals for WR99210, Greg Burri for the parasitemia software and the Advanced Light and Fluorescence Microscopy (ALFM) facility at the Centre for Structural Systems Biology (CSSB), in particular Roland Thuenauer, for support with light microscopy image recording and analysis. DSM1 (MRA-1161) was obtained from MR4/BEI Resources, NIAID, NIH. Furthermore, we thank Maria Rosenthal for her help with the visualization of the predicted protein structures.

Funding

AB and JSW were funded by the German Research Foundation (DFG) grant BA 5213/3-1. Partnership of Universität Hamburg and DESY (PIER) project ID PIF-2018-87 (JSTR, CL,

TWG), CSSB Seed grant KIF 2019/002 (TWG), Hospital Research Foundation Fellowship (DW), DAAD/Universities Australia joint research co-operation scheme (TWG, DW, BL). IH and BL were supported by Australian Government Research Training Stipend. JY, SG and GN were funded by DFG Projektnummer 374031971 TRR 240 A04 and 417451587. JSTÄ thanks the Jürgen Manchot Stiftung for funding and PMR, TS acknowledge funding by the DFG (SP1209/4-1)

Author contribution

Conceptualization: JSW, TWG, AB, JSTR
Methodology: GN, SG
Investigation: JSW, PMR, JY, GF; JSTÄ, HVT, AA, IH, BL
Formal Analysis: JSTR
Writing original manuscript: JSW, AB, JSTR, DW
Review & Editing: JSW, TWG, AB, JSTR, DW
Funding Acquisition: DW, CL, TWG, AB, JSTR
Resources: TWG
Project Administration: TWG, AB, JSTR
Supervision: DW, TS, SG, TWG, AB
All authors read and approved the manuscript.

Figures

Figure 1: Subcellular localization of six putative *P. falciparum* transporters during asexual blood stage development.

(A) Schematic representation of endogenous tagging strategy using the selection-linked integration system (SLI). pink, human dihydrofolate dehydrogenase (hDHFR); grey, homology region (HR); green, green fluorescence protein (GFP) tag; dark grey, T2A skip peptide; blue, neomycin resistance cassette; orange, glmS cassette. Stars indicate stop codons, and arrows depict primers (P1 to P4) used for the integration check PCR. (B–G) Localization of (B) *PfFVRT1*-GFP-glmS, (C) *PfZIP1*-GFP-glmS, (D) *PfCDF*-GFP-glmS, (E) *PfDMT2*-GFP-glmS, (F) *PfMFS6*-GFP-glmS and (G) *PfPMRT1*-GFP-glmS by live-cell microscopy in ring, trophozoite and schizont stage parasites. Nuclei were stained with Hoechst-33342. (H) Co-localization of the GFP-tagged putative transporters with marker proteins P40PX-mCherry (food vacuole), ACP-mCherry (apicoplast), Lyn-mCherry (parasite plasma membrane), ARO-mCherry (rhoptry) and AMA1-mCherry (microneme) as indicated. Nuclei were stained with Hoechst- 33342. Scale bar, 2 µm.

Figure 2: Conditional knockdown of putative transporter indicate importance of *PfDMT2* and *PfPMRT1* for parasites fitness.

(A–C) Live cell microscopy and quantification of knockdown by measuring mean fluorescence intensity (MFI) density and size (area) of (A) *PfDMT2*-GFP-glmS (B) *PfMFS6*-GFP-glmS and (C) *PfPMRT1*-GFP-glmS parasites 40 hours after treatment without (control) or with 2.5 mM glucosamine. Scale bar, 2 μ m. Statistics are displayed as mean $\pm$ SD of three (A–B) or four (C) independent experiments and individual data points are color-coded by experiments according to Superplots guidelines (101). P-values displayed were determined with two-tailed unpaired t-test. **(D)** Growth of parasites treated without (control) or with 2.5 mM glucosamine determined by flow cytometry is shown as relative parasitemia values after two cycles. Shown are means $\pm$ SD of three (*PfPMRT1*-GFP-glmS, *PfDMT2*-GFP-glmS, *PfMFS6*-GFP-glmS) and five (3D7 wild type parasites) independent growth experiments. P-values displayed were determined with unpaired t test with Welch correction and Benjamin Hochberg for multiple testing correction. Individual growth curves are shown in Figure S4G. **(E)** Growth of *PfPMRT1*-glmS and 3D7 parasites after treatment with 2.5 mM (left panel) or 5 mM glucosamine (right panel) compared to untreated control parasites over five consecutive days. **(F)** Mean $\pm$ SD distribution of ring and schizont stage parasites in *PfPMRT1*-glmS and 3D7 cell lines treated without (control), with 2.5 mM or 5 mM glucosamine at 80 hours post addition of glucosamine of three independent experiments.

Figure 3: *PfPMRT1* is essential for asexual blood stage development.

(A) Simplified schematic of DiCre-based conditional *PfPMRT1* knockout using selection-linked integration (SLI). Pink, human dihydrofolate dehydrogenase (hDHFR); grey, homology region (HR); green, T2A skip peptide; light blue, recodonized *PfPMRT1*; dark blue, 3xHA tag, yellow, neomycin phosphotransferase resistance cassette; orange, loxp sequence. Scissors indicate DiCre mediated excision sites upon addition of rapalog. Stars indicate stop codons, and arrows depict primers (P1 to P5) used for the integration check PCR and excision PCR. **(B)** Diagnostic PCR of unmodified wildtype and transgenic cond Δ PMRT1 knock-in (KI) cell line to check for genomic integration using Primer P1-P4 as indicated in (A). **(C)** Immunofluorescence assay (IFA) of cond Δ PMRT1 late stage schizont parasites showing localization of *PfPMRT1*-3xHA at the parasite plasma membrane (PPM) co-localizing with the merozoite surface protein 1 (MSP1). **(D)** Diagnostic PCR to verify the excision at genomic level at 24 hpi / 20 hours post rapalog addition for cond Δ PMRT1 and at 48 hpi for cond Δ PMRT1, c-^{nmd3}*PfPMRT1*-ty1 and c-^{sf3a2}*PfPMRT1*-ty1 parasites using Primer P1-P5 as indicated in (A). Black arrow head, original locus; red arrow head, excised locus. **(E)** Western blot using α -HA to verify knockout of *PfPMRT1* on protein level 4, 24 and 48 hours post invasion. Expected molecular weight of *PfPMRT1*-3xHA: 53.3 kDa. Antibodies detecting Aldolase and SBP1 were used as loading

controls. **(F)** Growth curves of $\text{cond}\Delta\text{PMRT1}$, $c\text{-}^{nmd3}P\text{fPMRT1-ty1}$ and $c\text{-}^{sf3a2}P\text{fPMRT1-ty1}$ parasites +/- rapalog monitored over five days by flow cytometry. One representative growth curve is depicted (replicates in Figure S5). Summary is shown as relative parasitemia values, which were obtained by dividing the parasitemia of rapalog treated cultures by the parasitemia of the corresponding untreated ones. Shown are means +/- SD of three ($\text{cond}\Delta\text{PMRT1}$, $c\text{-}^{nmd3}P\text{fPMRT1-ty1}$) or four ($c\text{-}^{sf3a2}P\text{fPMRT1-ty1}$) independent growth experiments. **(G)** IFA of $\text{cond}\Delta\text{PMRT1}$ complemented with C-terminal TY1-tagged $P\text{fPMRT1}$ constructs expressed either under the constitutive *nmd3* or the weak *sf3a2* promoter to verify PPM localization. Scale bar, 2 μm .

Figure 4: Knockout of $P\text{fPMRT1}$ results in accumulation of PPM-derived vacuoles and growth arrest at the trophozoite stage.

(A) Parasite stage distribution in Giemsa smears displayed as heatmap showing percentage of parasite stages for tightly synchronized (+/- 2 h) 3D7 control and $\text{cond}\Delta\text{PMRT1}$ (rapalog treated at 4 hpi, 20 hpi or 32 hpi) parasite cultures over two consecutive cycles. A second replicate is shown in Figure S6A **(B)** Giemsa smears of control and at 4 hpi rapalog treated $\text{cond}\Delta\text{PMRT1}$ parasites over two cycles. Scale bar, 5 μm . **(C)** Live cell microscopy of 4 hour window synchronized 3D7 control and $\text{cond}\Delta\text{PMRT1}$ parasites +/- rapalog stained with dihydroethidium (DHE) at 20–32 hpi. **(D)** Quantification of parasites displaying vacuoles (green) for 4 hour window synchronized 3D7 control and rapalog treated $\text{cond}\Delta\text{PMRT1}$ parasites. Shown are percentages of normal parasites versus parasites displaying vacuoles as means +/- SD of three independent experiments. **(E)** Live cell microscopy of 8 hour window synchronized 3D7 control and rapalog treated $\text{cond}\Delta\text{PMRT1}$ parasites, episomally expressing the PPM marker Lyn-mCherry at 24–40 hpi. **(F)** Live cell microscopy of 3D7 control and $\text{cond}\Delta\text{PMRT1}$ parasites +/- rapalog stained with BODIPY TR C5 ceramide at 32 hpi. Scale bar, 2 μm .

Figure 5: $P\text{fPMRT1}$ is essential for early gametocyte development.

(A) Live cell microscopy of 3D7-iGP- $P\text{fPMRT1}$ -GFP parasites across the complete gametocyte development. White arrow heads indicate remaining GDV1-GFP signal observed in close proximity to the Hoechst signal, as previously reported (56, 92, 102, 103). **(B)** Live cell microscopy of $P\text{fPMRT1}$ -GFP parasites expressing the PPM marker Lyn-mCherry. Nuclei were stained with Hoechst-33342. Scale bar, 2 μm . **(C)** Experimental setup of gametocyte induction upon GDV1-GFP-DD expression (+shield-1) and conditional $P\text{fPMRT1}$ knockout (+rapalog) and elimination of asexual blood stage parasites (+GlcNac). **(D)** Gametocyte development over 12 days of $\text{cond}\Delta\text{PMRT1}/\text{GDV1-GFP-DD}$ parasites without (control) or with

rapalog addition at day 3 (3 dpi) or day 5 (5 dpi) after induction of sexual commitment by conditional expression of GDV1-GFP upon addition of shield-1. Scale bar, 5 μ m. **(E)** Diagnostic PCR to verify the excision on genomic level at 5 dpi and 12 dpi. Black arrow head, original locus; red arrow head, excised locus. **(F)** Representative Giemsa smears and quantification of parasite stage distribution at day 10 post induction for parasites treated without (control) or with rapalog at day 3 post induction. For each condition parasitemia and parasite stages distribution in ($n_{\text{control}} = 3370, 2304, 2759$ and $n_{\text{rapalog}} = 3010, 1830, 2387$) erythrocytes were determined and are displayed as percentage (gametocyte parasitemia for control (1.3%, 0.4%, 1.1%) and for rapalog treated (0%, 0%, 0%). Nuclei were stained with Hoechst-33342. Scale bar, 10 μ m.

Figure 6: PMRT1 is a genus-specific transporter with conserved function.

(A) Phylogenetic tree of haemosporidian parasites (modified from (93)) containing PMRT1 homologous sequences associated with data on pairwise amino acid sequence identity to *PfPMRT1*. The phylogeny is derived from Bayesian Inference using BEAST using a fully partitioned amino acid dataset and lognormal relaxed molecular clock (93). Silhouettes depict representatives of the vertebrate hosts for each lineage and white filled bars indicate pairwise identities of PMRT1 homologs used for subsequent complementation assays. **(B)** Structural alignment of predicted *PfPMRT1* structure with Maquette-3 protein (PDB: 5vj1) (57). Both structures have a root mean square deviation (RMSD) over the aligned α -carbon position of 3.12 over 184 residues calculated in PyMol. **(C)** IFA of *c-nmd3Pk-ty1* and *c-nmd3Pv-ty1* parasites to verify correct localization of the expressed complementation fusion proteins at the parasite plasma membrane. Nuclei were stained with Hoechst-33342. Scale bar, 2 μ m. **(D)** Growth of Δ PMRT1 parasites complemented with *PfPMRT1* homologs from *P. vivax* (PVP01_0936100) and *P. knowlesi* (PKNH_0933400). Shown are relative parasitemia values, which were obtained by dividing the parasitemia of rapalog treated cultures by the parasitemia of the corresponding untreated controls together with means $\pm$ SD from three *c-nmd3Pf-ty1* (Δ *c-nmd3PfPMRT1-ty1* Figure 3D, S5B) and six (*c-nmd3Pk-ty1*, *c-nmd3Pv-ty1*) independent growth experiments. One sample t-test **(E)** Diagnostic PCR to verify the excision of *PfPMRT1* on genomic level at 48 hpi for *c-nmd3Pf-ty1*, *c-nmd3Pk-ty1* and *c-nmd3Pv-ty1* parasites. Black arrow head, original locus; red arrow head, excised locus.

Figure 7: In vitro characterization of PfPMRT1 in Xenopus oocytes.

(A) Surface electrostatics of the predicted *PfPMRT1* structure generated by APBS within PyMol. **(B)** Scheme of *PfPMRT1* membrane topology prediction and the two mutation sites: Outer loop mutant (MutPV) between TM 1 – 2 with negative charged amino acids (indicated in

red) and inner loop mutant (MutPC) between TM 4 – 5 with positive charged amino acids (indicated in blue) were changed to neutral amino acids. The cartoon was generated by Protter(104) and PyMol. **(C)** Confocal images of a non-injected oocyte, *PfPMRT1*, MutPV and MutPC expressing oocytes. Scale bar, 100 μ m. **(D)** Superimposed traces of control (injected with a cyclic nucleotide-gated potassium channel SthK(77)), *PfPMRT1*, MutPV and MutPC expressing oocytes with the protocol shown in the upper left. The grey traces are original recordings from 7 to 10 oocytes, averaged traces are shown in black. Bath solution contains (in mM): 120 NMG Cl, 1 MgCl₂, 2 CaCl₂, 10 HEPES, pH7.6. **(E)** Current–voltage (I–V) curves of data points from (D) taken at the end of each holding potential. Both, MutPV and the SthK-control are significantly different from wild type *PfPMRT1* with P values of 0.017 and 0.014, respectively (Mean $\pm$ SD, n = 7 - 10). **(F)** Diagnostic PCR to verify the excision on genomic level at 48 hours post rapalog addition in *cond Δ PMRT1*, *c^{nmd3}MutPC-ty1* and *c^{nmd3}MutPV-ty1* parasites +/- rapalog. Black arrow head, original locus; red arrow head, excised locus. **(G)** Parasite growth shown as relative parasitemia values, which were obtained by dividing the parasitemia of rapalog treated cultures by the parasitemia of the corresponding untreated controls. Shown are means $\pm$ SD of four (*c^{sf3a2}ty1*), three (*c^{nmd3}ty1*, *c^{nmd3}MutPC-ty1*), or six (*c^{nmd3}MutPV-ty1*) independent growth experiments. One sample t-test was used to test for statistical differences between complemented cell lines and plus and minus rapalog treatment.

Figure S1: Structure predictions and structure homology search of candidate proteins

(A) AlphaFold structure predictions of the six selected orphan transporters visualized in PyMol. **(B)** Results from protein structure comparison server Dali using the AlphaFold-generated PDB files of the selected transporters as input structure. Shown are the top five non-redundant hits with Z score (significance estimate), msd (difference between the root-mean-square-deviation (rmsd) value associated with a protein structure pair and the rmsd value that would have been observed in the case that the two structures had the same crystallographic resolution), lali (number of aligned positions), nres (number of residues in the matched structure) and %id (the percentage sequence identity in the match).

Figure S2: Validation of generated transgenic cell lines by PCR and Western blot.

(A) Confirmatory PCR of unmodified wildtype (WT) and transgenic knock-in (KI) cell lines (PF3D7_0523800-GFP-glmS (*PfFVRT1*), PF3D7_0609100-GFP-glmS (*PfZIP1*), PF3D7_0715900-GFP-glmS (*PfCDF*), PF3D7_0716900-GFP-glmS (*PfDMT2*), PF3D7_1440800-GFP-glmS (*PfMFS6*) and PF3D7_1135300-GFP-glmS (*PfPMRT1*)) to check for genomic integration at the 3'- and 5'-end of the locus. Position of the primer used are indicated with numbered arrows in Figure 1A. **(B)** Western Blot analysis of wildtype (3D7) and

knock-in (KI) cell lines using mouse anti-GFP to detect the tagged full-length protein (upper panel) and rabbit anti-aldolase to control for equal loading (lower panel). Protein size is indicated in kDa. Expected molecular weight for GFP fusion proteins: *PfFVRT1* (107.5 kDa), *PfZIP1* (69.0 kDa), *PfDMT2* (66.4 kDa), *PfMFS6* (98.8 kDa), *PfPMRT1* (77.5 kDa), *PfCDF* (91.6 kDa) **(C)** Localization of *PfCDF*-3xHA by IFA in ring, trophozoite and schizont parasites. Nuclei were stained with Hoechst. Diagnostic PCR of unmodified wildtype (WT) and transgenic knock-in (KI) cell line. **(D)** Localization of *PfPMRT1*_2xFKBP-GFP across the IDC. Nuclei were stained with DAPI. Scale bar, 2 μ m. Diagnostic PCR of unmodified wildtype (WT) and transgenic knock-in (KI) cell line. (E) Localization of *PfZIP1*-GFP in merozoites. Nuclei were stained with DAPI. Scale bar, 2 μ m.

Figure S3: Targeted gene disruption (TGD) of *PfZIP1* and *PfCDF*.

(A) Schematic representation of TGD strategy using the selection-linked integration system (SLI). pink, human dihydrofolate dehydrogenase (hDHFR); grey, homology region (HR); green, green fluorescence protein (GFP) tag; dark grey, T2A skip peptide; blue, neomycin resistance cassette. Stars indicate stop codons, and arrows depict primers (P1 to P4) used for the integration check PCR. **(B)** Localization of *PfZIP1*-TGD-GFP in ring, trophozoite and schizont parasites. Nuclei were stained with Hoechst-33342. Scale bar, 2 μ m. Confirmatory PCR of unmodified wildtype (WT) and transgenic targeted gene disruption (TGD) cell line. Growth curves of *PfZIP1*-TGD vs. 3D7 parasites monitored over five days by FACS. Three independent growth experiments were performed and a summary is shown as percentage of growth compared to 3D7 parasites. **(C)** Localization of *PfCDF*-TGD in ring, trophozoite and schizont parasites. Nuclei were stained with DAPI. Confirmatory PCR of unmodified wildtype (WT) and transgenic targeted gene disruption (TGD) cell line. Scale bar, 1 μ m.

Figure S4: Conditional knockdown via glmS system.

Live cell microscopy of **(A)** *PfFVRT1*-GFP-glmS, **(B)** *PfCDF*-GFP-glmS, **(C)** *PfZIP1*-GFP-glmS **(D)** *PfDMT2*-GFP-glmS, **(E)** *PfMFS6*-GFP-glmS and **(F)** *PfPMRT1*-GFP-glmS parasites 40 hours after treatment without (control) or with 2.5 mM Glucosamine. Nuclei were stained with Hoechst-33342. Scale bar, 2 μ m. **(G)** Individual growth curves of the growth assays shown in Figure 2D.

Figure S5: Conditional knockout of *PfPMRT1* via DiCre-based system

Replicates of growth curves of *cond Δ PMRT1*, *c^{-nmd3}PfPMRT1-ty1* and *c^{-sf3a2}PfPMRT1-ty1* parasites +/- rapalog monitored over five days by FACS shown in Figure 3.

Figure S6: Conditional knockout of *PfPMRT1*

(A) Parasite stage distribution in Giemsa smears displayed as heatmap showing percentage of stages for control, 4 hpi, 20 hpi or 32 hpi rapalog treated 4 hour window synchronized Δ PMRT1 parasite cultures over one cycle. (B) Giemsa smears of control and 4 hpi, 20 hpi or 32 hpi rapalog treated parasites at 4, 16, 20, 24, 32, 40 and 48 hpi. Scale bar, 5 μ m.

Figure S7: Conditional knockdown of *PfPMRT1* has no effect during gametocyte development.

(A) Confirmatory PCR of unmodified wildtype (WT) and transgenic 3D7-iGP-*PfPMRT1*-GFP-glmS to check for genomic integration at the 3'- and 5'-end of the locus. Position of the primer used are indicated with numbered arrows in Figure 1A. (B) Schematic representation of the experimental setup. (C) Live cell microscopy of 3D7-iGP-*PfPMRT1*-GFP stage I – V gametocytes. Scale bar, 2 μ m. (D) Giemsa smears of stage I – V gametocytes cultured either without (control) or with 2.5 mM glucosamine. Scale bar, 5 μ m. (E) Quantification of knockdown by measuring mean fluorescence intensity (MFI) density and size (area) of parasites at day 7 and day 12 post induction of gametocytogenesis cultured either without (control) or with 2.5 mM glucosamine. Scale bar, 2 μ m. Statistics are displayed as mean $\pm$ SD of four independent experiments and individual data points are displayed as scatterplot color-coded by experiments according to Superplots guidelines(101)(101). P-values displayed were determined with two-tailed unpaired t-test. (F) For each condition gametocytemia at day 10 post gametocyte induction was determined by counting between 1256-2653 (mean 2147) cells per condition in Giemsa-stained thin blood smears. Displayed are means $\pm$ SD of independent growth experiments with the number of experiments (n) indicated. P-values displayed were determined with two-tailed unpaired t-test.

Figure S8: Individual growth curves of c-*nmd3**Pk*-ty1 (A) and c-*nmd3**Pv*-ty1 (B) parasites +/- rapalog monitored over two IDCs by FACS shown in Figure 6.

Figure S9: Individual growth curves of c-*nmd3*MutIn-ty1 (A) and c-*nmd3*MutOut-ty1 (B) parasites +/- rapalog monitored over two IDCs by FACS shown in Figure 7. (C) IFA of c-*nmd3*MutPC-ty1 and c-*nmd3*MutPV-ty1 parasites to verify correct localization at the parasite plasma membrane. Nuclei were stained with Hoechst-33342. Scale bar, 2 μ m.

Table S1: Oligonucleotides and plasmids used in this study

References

1. Martin RE, Henry RI, Abbey JL, Clements JD, Kirk K. 2005. The “permeome” of the malaria parasite: an overview of the membrane transport proteins of *Plasmodium falciparum*. *Genome Biol* 6:R26.
2. Martin RE. 2020. The transportome of the malaria parasite. *Biol Rev Camb Philos Soc* 95:305–332.
3. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan M-S, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DMA, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B. 2002. Genome sequence of the human malaria parasite *Plasmodium falciparum*. *Nature* 419:498–511.
4. Martin RE, Ginsburg H, Kirk K. 2009. Membrane transport proteins of the malaria parasite. *Mol Microbiol*. John Wiley & Sons, Ltd (10.1111).
5. Weiner J, Kooij TWA. 2016. Phylogenetic profiles of all membrane transport proteins of the malaria parasite highlight new drug targets. *Microb Cell* 3:511–521.
6. Dean P, Major P, Nakjang S, Hirt RP, Martin Embley T. 2014. Transport proteins of parasitic protists and their role in nutrient salvage. *Front Plant Sci*. Frontiers Research Foundation.
7. Foote SJ, Thompson JK, Cowman AF, Kemp DJ. 1989. Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of *P. falciparum*. *Cell* 57:921–930.
8. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LMB, Bir Singh Sidhu A, Naudé B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellem TE. 2000. Mutations in the *P. falciparum* digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. *Mol Cell* 6:861–871.
9. Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnädig N, Uhlemann AC, Martin RE, Lehane AM, Fidock DA. 2016. Globally prevalent PfMDR1 mutations modulate *Plasmodium falciparum* susceptibility to artemisinin-based combination therapies. *Nat Commun* 7.
10. Rijpma SR, Van Der Velden M, Bilos A, Jansen RS, Mahakena S, Russel FGM, Sauerwein RW, Van De Wetering K, Koenderink JB. 2016. MRP1 mediates folate transport and antifolate sensitivity in *Plasmodium falciparum*. *FEBS Lett* 590:482–492.
11. Mesén-Ramírez P, Bergmann B, Elhabiri M, Zhu L, Thien H von, Castro-Peña C, Gilberger T-W, Davioud-Charvet E, Bozdech Z, Bachmann A, Spielmann T. 2021. The

- 912 parasitophorous vacuole nutrient pore is critical for drug access in malaria parasites and
913 modulates the fitness cost of artemisinin resistance. *Cell Host Microbe* 0:283.
- 914 12. Cowman AF, Galatis D, Thompson JK. 1994. Selection for mefloquine resistance in
915 *Plasmodium falciparum* is linked to amplification of the *pfmpr1* gene and cross-
916 resistance to halofantrine and quinine. *Proc Natl Acad Sci U S A* 91:1143–1147.
- 917 13. Mok S, Liong KY, Lim EH, Huang X, Zhu L, Preiser PR, Bozdech Z. 2014. Structural
918 polymorphism in the promoter of *pfmpr2* confers *Plasmodium falciparum* tolerance to
919 quinoline drugs. *Mol Microbiol* 91:918–934.
- 920 14. Lim MYX, LaMonte G, Lee MCS, Reimer C, Tan BH, Corey V, Tjahjadi BF, Chua A,
921 Nachon M, Wintjens R, Gedeck P, Malleret B, Renia L, Bonamy GMC, Ho PCL, Yeung
922 BKS, Chow ED, Lim L, Fidock DA, Diagana TT, Winzeler EA, Bifani P. 2016. UDP-
923 galactose and acetyl-CoA transporters as *Plasmodium* multidrug resistance genes. *Nat*
924 *Microbiol* 1.
- 925 15. Richards SN, Nash MN, Baker ES, Webster MW, Lehane AM, Shafik SH, Martin RE.
926 2016. Molecular Mechanisms for Drug Hypersensitivity Induced by the Malaria
927 Parasite's Chloroquine Resistance Transporter. *PLoS Pathog* 12.
- 928 16. Cowell AN, Istvan ES, Lukens AK, Gomez-Lorenzo MG, Vanaerschot M, Sakata-Kato
929 T, Flannery EL, Magistrado P, Owen E, Abraham M, La Monte G, Painter HJ, Williams
930 RM, Franco V, Linares M, Arriaga I, Bopp S, Corey VC, Gnädig NF, Coburn-Flynn O,
931 Reimer C, Gupta P, Murithi JM, Moura PA, Fuchs O, Sasaki E, Kim SW, Teng CH,
932 Wang LT, Akidil A, Adjalley S, Willis PA, Siegel D, Tanaseichuk O, Zhong Y, Zhou Y,
933 Llinás M, Otilie S, Gamo FJ, Lee MCS, Goldberg DE, Fidock DA, Wirth DF, Winzeler
934 EA. 2018. Mapping the malaria parasite druggable genome by using in vitro evolution
935 and chemogenomics. *Science* (80-) 359:191–199.
- 936 17. Rocamora F, Gupta P, Istvan ES, Luth MR, Carpenter EF, Kümpornsin K, Sasaki E,
937 Calla J, Mittal N, Carolino K, Owen E, Llinás M, Otilie S, Goldberg DE, Lee MCS,
938 Winzeler EA. 2021. PfMFR3: A Multidrug-Resistant Modulator in *Plasmodium*
939 *falciparum*. *ACS Infect Dis* 7:811–825.
- 940 18. Kirk K. 2004. Channels and transporters as drug targets in the *Plasmodium*-infected
941 erythrocyte. *Acta Trop* 89:285–298.
- 942 19. Koenderink JB, Kavishe RA, Rijpma SR, Russel FGM. 2010. The ABCs of multidrug
943 resistance in malaria. *Trends Parasitol.* *Trends Parasitol.*
- 944 20. Murithi JM, Deni I, Pasaje CFA, Okombo J, Bridgford JL, Gnädig NF, Edwards RL, Yeo
945 T, Mok S, Burkhard AY, Coburn-Flynn O, Istvan ES, Sakata-Kato T, Gomez-Lorenzo
946 MG, Cowell AN, Wicht KJ, Le Manach C, Kalantarov GF, Dey S, Duffey M, Laleu B,
947 Lukens AK, Otilie S, Vanaerschot M, Trakht IN, Gamo F-J, Wirth DF, Goldberg DE,
948 Odom John AR, Chibale K, Winzeler EA, Niles JC, Fidock DA. 2021. The *Plasmodium*

- 949 falciparum ABC transporter ABCI3 confers parasite strain-dependent pleiotropic
950 antimalarial drug resistance. *Cell Chem Biol* 0.
- 951 21. Counihan NA, Modak JK, de Koning-Ward TF. 2021. How Malaria Parasites Acquire
952 Nutrients From Their Host. *Front Cell Dev Biol* 9:582.
- 953 22. Saliba KJ, Horner HA, Kirk K. 1998. Transport and metabolism of the essential vitamin
954 pantothenic acid in human erythrocytes infected with the malaria parasite *Plasmodium*
955 *falciparum*. *J Biol Chem* 273:10190–10195.
- 956 23. Gulati S, Ekland EH, Ruggles K V., Chan RB, Jayabalasingham B, Zhou B, Mantel PY,
957 Lee MCS, Spottiswoode N, Coburn-Flynn O, Hjelmqvist D, Worgall TS, Marti M, Di
958 Paolo G, Fidock DA. 2015. Profiling the Essential Nature of Lipid Metabolism in Asexual
959 Blood and Gametocyte Stages of *Plasmodium falciparum*. *Cell Host Microbe* 18:371–
960 381.
- 961 24. Mamoun C Ben, Prigge ST, Vial H. 2010. Targeting the lipid metabolic pathways for the
962 treatment of malaria. *Drug Dev Res*. John Wiley & Sons, Ltd.
- 963 25. Garten M, Beck JR. 2021. Structured to conquer: transport across the *Plasmodium*
964 parasitophorous vacuole. *Curr Opin Microbiol*. Elsevier Ltd.
- 965 26. Kloehn J, Lacour CE, Soldati-Favre D. 2021. The metabolic pathways and transporters
966 of the plastid organelle in Apicomplexa. *Curr Opin Microbiol* 63:250–258.
- 967 27. Beck JR, Ho CM. 2021. Transport mechanisms at the malaria parasite-host cell
968 interface. *PLoS Pathog*. Public Library of Science.
- 969 28. Kenthirapalan S, Waters AP, Matuschewski K, Kooij TWA. 2016. Functional profiles of
970 orphan membrane transporters in the life cycle of the malaria parasite. *Nat Commun*
971 7:10519.
- 972 29. Sayers CP, Mollard V, Buchanan HD, McFadden GI, Goodman CD. 2018. A genetic
973 screen in rodent malaria parasites identifies five new apicoplast putative membrane
974 transporters, one of which is essential in human malaria parasites. *Cell Microbiol*
975 20:e12789.
- 976 30. Ginsburg H. 2006. Progress in in silico functional genomics: the malaria Metabolic
977 Pathways database. *Trends Parasitol* 22:238–240.
- 978 31. Otto TD, Wilinski D, Assefa S, Keane TM, Sarry LR, Böhme U, Lemieux J, Barrell B,
979 Pain A, Berriman M, Newbold C, Llinás M. 2010. New insights into the blood-stage
980 transcriptome of *Plasmodium falciparum* using RNA-Seq. *Mol Microbiol* 76:12–24.
- 981 32. Wichers JS, Scholz JAM, Strauss J, Witt S, Lill A, Ehnold LI, Neupert N, Liffner B,
982 Lühken R, Petter M, Lorenzen S, Wilson DW, Löw C, Lavazec C, Bruchhaus I, Tannich
983 E, Gilberger TW, Bachmann A. 2019. Dissecting the gene expression, localization,
984 membrane topology, and function of the *plasmodium falciparum* STEVOR protein
985 family. *MBio* 10:e01500-19.

- 986 33. Treeck M, Sanders JL, Elias JE, Boothroyd JC. 2011. The phosphoproteomes of
987 plasmodium falciparum and toxoplasma gondii reveal unusual adaptations within and
988 beyond the parasites' boundaries. Cell Host Microbe 10:410–419.
- 989 34. Pease BN, Huttlin EL, Jedrychowski MP, Talevich E, Harmon J, Dillman T, Kannan N,
990 Doerig C, Chakrabarti R, Gygi SP, Chakrabarti D. 2013. Global analysis of protein
991 expression and phosphorylation of three stages of plasmodium falciparum
992 intraerythrocytic development. J Proteome Res 12:4028–4045.
- 993 35. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool
994 K, Bates R, Žídek A, Potapenko A, Bridgland A, Meyer C, Kohl SAA, Ballard AJ, Cowie
995 A, Romera-Paredes B, Nikolov S, Jain R, Adler J, Back T, Petersen S, Reiman D,
996 Clancy E, Zielinski M, Steinegger M, Pacholska M, Berghammer T, Bodenstein S, Silver
997 D, Vinyals O, Senior AW, Kavukcuoglu K, Kohli P, Hassabis D. 2021. Highly accurate
998 protein structure prediction with AlphaFold. Nature 596:583–589.
- 999 36. Holm L. 2020. DALI and the persistence of protein shape. Protein Sci 29:128–140.
- 1000 37. Birnbaum J, Flemming S, Reichard N, Soares AB, Mesén-Ramírez P, Jonscher E,
1001 Bergmann B, Spielmann T. 2017. A genetic system to study Plasmodium falciparum
1002 protein function. Nat Methods 14:450–456.
- 1003 38. Prommana P, Uthapibull C, Wongsombat C, Kamchonwongpaisan S, Yuthavong Y,
1004 Knuepfer E, Holder AA, Shaw PJ. 2013. Inducible Knockdown of Plasmodium Gene
1005 Expression Using the glmS Ribozyme. PLoS One 8:e73783.
- 1006 39. Tawk L, Chicanne G, Dubremetz J-F, Richard V, Payrastre B, Vial HJ, Roy C, Wengelnik
1007 K. 2010. Phosphatidylinositol 3-Phosphate, an Essential Lipid in Plasmodium, Localizes
1008 to the Food Vacuole Membrane and the Apicoplast. Eukaryot Cell 9:1519–1530.
- 1009 40. Jonscher E, Flemming S, Schmitt M, Sabitzki R, Reichard N, Birnbaum J, Bergmann B,
1010 Höhn K, Spielmann T. 2019. PfVPS45 Is Required for Host Cell Cytosol Uptake by
1011 Malaria Blood Stage Parasites. Cell Host Microbe 25:166-173.e5.
- 1012 41. Waller RF, Reed MB, Cowman AF, McFadden GI. 2000. Protein trafficking to the plastid
1013 of Plasmodium falciparum is via the secretory pathway. EMBO J 19:1794–1802.
- 1014 42. Birnbaum J, Scharf S, Schmidt S, Jonscher E, Hoeijmakers WAM, Flemming S,
1015 Toenhake CG, Schmitt M, Sabitzki R, Bergmann B, Fröhlke U, Mesén-Ramírez P,
1016 Blancke Soares A, Herrmann H, Bártfai R, Spielmann T. 2020. A Kelch13-defined
1017 endocytosis pathway mediates artemisinin resistance in malaria parasites. Science (80-
1018) 367:51–59.
- 1019 43. Inoue T, Heo W Do, Grimley JS, Wandless TJ, Meyer T. 2005. An inducible translocation
1020 strategy to rapidly activate and inhibit small GTPase signaling pathways. Nat Methods
1021 2:415–418.
- 1022 44. Cabrera A, Herrmann S, Warszta D, Santos JM, John Peter AT, Kono M, Debrouver S,

- Jacobs T, Spielmann T, Ungermann C, Soldati-Favre D, Gilberger TW. 2012. Dissection of Minimal Sequence Requirements for Rhoptry Membrane Targeting in the Malaria Parasite. *Traffic* 13:1335–1350.
45. Geiger M, Brown C, Wichers JS, Strauss J, Lill A, Thuenauer R, Liffner B, Wilcke L, Lemcke S, Heincke D, Pazicky S, Bachmann A, Löw C, Wilson DW, Filarsky M, Burda P-C, Zhang K, Junop M, Gilberger TW. 2020. Structural Insights Into PfARO and Characterization of its Interaction With PfAIP. *J Mol Biol* 432:878–896.
46. Peterson MG, Marshall VM, Smythe JA, Crewther PE, Lew A, Silva A, Anders RF, Kemp DJ. 1989. Integral membrane protein located in the apical complex of *Plasmodium falciparum*. *Mol Cell Biol* 9:3151–3154.
47. Wichers JS, Wunderlich J, Heincke D, Pazicky S, Strauss J, Schmitt M, Kimmel J, Wilcke L, Scharf S, von Thien H, Burda P, Spielmann T, Löw C, Filarsky M, Bachmann A, Gilberger TW. 2021. Identification of novel inner membrane complex and apical annuli proteins of the malaria parasite *Plasmodium falciparum*. *Cell Microbiol* 23:e13341.
48. Jullien N, Goddard I, Selmi-Ruby S, Fina J-L, Cremer H, Herman J-P. 2007. Conditional Transgenesis Using Dimerizable Cre (DiCre). *PLoS One* 2:e1355.
49. Andenmatten N, Egarter S, Jackson AJ, Jullien N, Herman JP, Meissner M. 2013. Conditional genome engineering in *Toxoplasma gondii* uncovers alternative invasion mechanisms. *Nat Methods* 10:125–127.
50. Holder AA, Lockyer MJ, Odink KG, Sandhu JS, Riveros-Moreno V, Nicholls SC, Hillman Y, Davey LS, Tizard MLV, Schwarz RT, Freeman RR. 1985. Primary structure of the precursor to the three major surface antigens of *Plasmodium falciparum* merozoites. *Nature* 317:270–273.
51. Mesén-Ramírez P, Bergmann B, Tran TT, Garten M, Stäcker J, Naranjo-Prado I, Höhn K, Zimmerberg J, Spielmann T. 2019. EXP1 is critical for nutrient uptake across the parasitophorous vacuole membrane of malaria parasites. *PLoS Biol* 17:e3000473.
52. López-Barragán MJ, Lemieux J, Quiñones M, Williamson KC, Molina-Cruz A, Cui K, Barillas-Mury C, Zhao K, Su X zhuan. 2011. Directional gene expression and antisense transcripts in sexual and asexual stages of *Plasmodium falciparum*. *BMC Genomics* 12:587.
53. Lasonder E, Rijpma SR, Van Schaijk BCL, Hoeijmakers WAM, Kensche PR, Gresnigt MS, Italiaander A, Vos MW, Woestenenk R, Bousema T, Mair GR, Khan SM, Janse CJ, Bártfai R, Sauerwein RW. 2016. Integrated transcriptomic and proteomic analyses of *P. Falciparum* gametocytes: Molecular insight into sex-specific processes and translational repression. *Nucleic Acids Res* 44:6087–6101.
54. Gómez-Díaz E, Yerbanga RS, Lefèvre T, Cohuet A, Rowley MJ, Ouedraogo JB, Corces

- VG. 2017. Epigenetic regulation of *Plasmodium falciparum* clonally variant gene expression during development in *Anopheles gambiae*. *Sci Rep* 7.
55. Boltryk SD, Passeecker A, Alder A, Carrington E, van de Vegte-Bolmer M, van Gemert G-J, van der Starre A, Beck H-P, Sauerwein RW, Kooij TWA, Brancucci NMB, Proellocks NI, Gilberger T-W, Voss TS. 2021. CRISPR/Cas9-engineered inducible gametocyte producer lines as a valuable tool for *Plasmodium falciparum* malaria transmission research. *Nat Commun* 12:4806.
56. Filarsky M, Fraschka SA, Niederwieser I, Brancucci NMB, Carrington E, Carrió E, Moes S, Jenoe P, Bártfai R, Voss TS. 2018. GDV1 induces sexual commitment of malaria parasites by antagonizing HP1-dependent gene silencing. *Science* (80-) 359:1259–1263.
57. Ennist NM, Stayrook SE, Dutton PL, Moser CC. 2017. 5VJT: De Novo Photosynthetic Reaction Center Protein Equipped with Heme B and Zn(II) cations. doi: [10.2210/pdb5vjt/pdb](https://doi.org/10.2210/pdb5vjt/pdb)
58. Sonnhammer EL, von Heijne G, Krogh A. 1998. A hidden Markov model for predicting transmembrane helices in protein sequences. *Proceedings Int Conf Intell Syst Mol Biol* 6:175–82.
59. Käll L, Krogh A, Sonnhammer ELL. 2004. A combined transmembrane topology and signal peptide prediction method. *J Mol Biol* 338:1027–1036.
60. Aurecochea C, Brestelli J, Brunk BP, Dommer J, Fischer S, Gajria B, Gao X, Gingle A, Grant G, Harb OS, Heiges M, Innamorato F, Iodice J, Kissinger JC, Kraemer E, Li W, Miller JA, Nayak V, Pennington C, Pinney DF, Roos DS, Ross C, Stoeckert CJ, Treatman C, Wang H. 2009. PlasmoDB: a functional genomic database for malaria parasites. *Nucleic Acids Res* 37:D539–D543.
61. Wunderlich J, Rohrbach P, Dalton JP. 2012. The malaria digestive vacuole. *Front Biosci (Schol Ed)* 4:1424–48.
62. Tabuchi M, Yoshimori T, Yamaguchi K, Yoshida T, Kishi F. 2000. Human NRAMP2/DMT1, which mediates iron transport across endosomal membranes, is localized to late endosomes and lysosomes in HEp-2 cells. *J Biol Chem* 275:22220–22228.
63. Zhang M, Wang C, Otto TD, Oberstaller J, Liao X, Adapa SR, Udenze K, Bronner IF, Casandra D, Mayho M, Brown J, Li S, Swanson J, Rayner JC, Jiang RHY, Adams JH. 2018. Uncovering the essential genes of the human malaria parasite *Plasmodium falciparum* by saturation mutagenesis. *Science* 360:eaap7847.
64. Kennedy K, Cobbold SA, Hanssen E, Birnbaum J, Spillman NJ, McHugh E, Brown H, Tilley L, Spielmann T, McConville MJ, Ralph SA. 2019. Delayed death in the malaria parasite *Plasmodium falciparum* is caused by disruption of prenylation-dependent

intracellular trafficking. PLOS Biol 17:e3000376.

65. Pasaje CFA, Cheung V, Kennedy K, Lim EE, Baell JB, Griffin MDW, Ralph SA. 2016. Selective inhibition of apicoplast tryptophanyl-tRNA synthetase causes delayed death in *Plasmodium falciparum*. Sci Rep 6:1–13.

66. Yeh E, DeRisi JL. 2011. Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage *plasmodium falciparum*. PLoS Biol 9.

67. Bushell E, Gomes AR, Sanderson T, Anar B, Girling G, Herd C, Metcalf T, Modrzynska K, Schwach F, Martin RE, Mather MW, McFadden GI, Parts L, Rutledge GG, Vaidya AB, Wengelnik K, Rayner JC, Billker O. 2017. Functional Profiling of a *Plasmodium* Genome Reveals an Abundance of Essential Genes. Cell 170:260-272.e8.

68. Chasen NM, Stasic AJ, Asady B, Coppens I, Moreno SNJ. 2019. The Vacuolar Zinc Transporter TgZnT Protects *Toxoplasma gondii* from Zinc Toxicity. mSphere 4:e00086-19.

69. Jiang Y, Wei J, Cui H, Liu C, Zhi Y, Jiang Z, Li Z, Li S, Yang Z, Wang X, Qian P, Zhang C, Zhong C, Su X, Yuan J. 2020. An intracellular membrane protein *GEP1* regulates xanthurenic acid induced gametogenesis of malaria parasites. Nat Commun 11:1764.

70. Liu W, Sundararaman SA, Loy DE, Learn GH, Li Y, Plenderleith LJ, Ndjango JBN, Speede S, Atencia R, Cox D, Shaw GM, Ayoub A, Peeters M, Rayner JC, Hahn BH, Sharp PM. 2016. Multigenomic delineation of *Plasmodium* species of the *Laverania* subgenus infecting wild-living chimpanzees and gorillas. Genome Biol Evol 8:1929–1939.

71. Zanghì G, Vembar SS, Baumgarten S, Ding S, Guizetti J, Bryant JM, Mattei D, Jensen ATR, Rénia L, Goh YS, Sauerwein R, Hermsen CC, Franetich J-F, Bordessoulles M, Silvie O, Soulard V, Scatton O, Chen P, Mecheri S, Mazier D, Scherf A. 2018. A Specific PfEMP1 Is Expressed in *P. falciparum* Sporozoites and Plays a Role in Hepatocyte Infection. Cell Rep 22:2951–2963.

72. Howick VM, Russell AJC, Andrews T, Heaton H, Reid AJ, Natarajan K, Butungi H, Metcalf T, Verzier LH, Rayner JC, Berriman M, Herren JK, Billker O, Hemberg M, Talman AM, Lawniczak MKN. 2019. The malaria cell atlas: Single parasite transcriptomes across the complete *Plasmodium* life cycle. Science (80-) 365.

73. Burda P-C, Crosskey T, Lauk K, Zurborg A, Söhnchen C, Liffner B, Wilcke L, Strauss J, Jeffries CM, Svergun DI, Wilson DW, Wilmanns M, Gilberger T-W, Pietsch E, Strauss J, Jeffries CM, Svergun DI, Wilson DW, Wilmanns M, Gilberger T-W. 2020. Structure-Based Identification and Functional Characterization of a Lipocalin in the Malaria Parasite *Plasmodium falciparum*. Cell Rep 31:107817.

74. Auburn S, Böhme U, Steinbiss S, Trimarsanto H, Hostetler J, Sanders M, Gao Q, Nosten F, Newbold CI, Berriman M, Price RN, Otto TD. 2016. A new *Plasmodium vivax*

reference sequence with improved assembly of the subtelomeres reveals an abundance of pir genes. Wellcome Open Res 1:4.

75. Pain A, Böhme U, Berry AE, Mungall K, Finn RD, Jackson AP, Mourier T, Mistry J, Pasini EM, Aslett MA, Balasubramaniam S, Borgwardt K, Brooks K, Carret C, Carver TJ, Cherevach I, Chillingworth T, Clark TG, Galinski MR, Hall N, Harper D, Harris D, Hauser H, Ivens A, Janssen CS, Keane T, Larke N, Lapp S, Marti M, Moule S, Meyer IM, Ormond D, Peters N, Sanders M, Sanders S, Sargeant TJ, Simmonds M, Smith F, Squares R, Thurston S, Tivey AR, Walker D, White B, Zuiderwijk E, Churcher C, Quail MA, Cowman AF, Turner CMR, Rajandream MA, Kocken CHM, Thomas AW, Newbold CI, Barrell BG, Berriman M. 2008. The genome of the simian and human malaria parasite *Plasmodium knowlesi*. *Nature* 455:799–803.
76. Liman ER, Tytgat J, Hess P. 1992. Subunit stoichiometry of a mammalian K⁺ channel determined by construction of multimeric cDNAs. *Neuron* 9:861–871.
77. Beck S, Yu-Strzelczyk J, Pauls D, Constantin OM, Gee CE, Ehmann N, Kittel RJ, Nagel G, Gao S. 2018. Synthetic Light-Activated Ion Channels for Optogenetic Activation and Inhibition. *Front Neurosci* 12:643.
78. Trager W, Jensen JB. 1997. Continuous culture of *Plasmodium falciparum*: its impact on malaria research. *Int J Parasitol* 27:989–1006.
79. Lambros C, Vanderberg JP. 1979. Synchronization of *Plasmodium falciparum* Erythrocytic Stages in Culture. *J Parasitol* 65:418.
80. Ponnudurai T, Lensen AHW, Meis JFGM, Meuwissen JHE. 1986. Synchronization of *Plasmodium falciparum* gametocytes using an automated suspension culture system. *Parasitology* 93:263–274.
81. Rivadeneira E, Wasserman M, Espinal C. 1983. Separation and Concentration of Schizonts of *Plasmodium falciparum* by Percoll Gradients. *J Protozool* 30:367–370.
82. Moon RW, Hall J, Rangkuti F, Ho YS, Almond N, Mitchell GH, Pain A, Holder AA, Blackman MJ. 2013. Adaptation of the genetically tractable malaria pathogen *Plasmodium knowlesi* to continuous culture in human erythrocytes. *Proc Natl Acad Sci* 110:531–536.
83. Ganesan SM, Morrissey JM, Ke H, Painter HJ, Laroiya K, Phillips MA, Rathod PK, Mather MW, Vaidya AB. 2011. Yeast dihydroorotate dehydrogenase as a new selectable marker for *Plasmodium falciparum* transfection. *Mol Biochem Parasitol* 177:29–34.
84. Grüning C, Spielmann T. 2012. Imaging of live malaria blood stage parasites. *Methods Enzymol* 506:81–92.
85. Bachmann A, Scholz JAM, Janßen M, Klinkert M-Q, Tannich E, Bruchhaus I, Petter M. 2015. A comparative study of the localization and membrane topology of members of the RIFIN, STEVOR and PfMC-2TM protein families in *Plasmodium falciparum*-infected

erythrocytes. *Malar J* 14:274.

86. Collins CR, Hackett F, Strath M, Penzo M, Withers-Martinez C, Baker DA, Blackman MJ. 2013. Malaria Parasite cGMP-dependent Protein Kinase Regulates Blood Stage Merozoite Secretory Organelle Discharge and Egress. *PLoS Pathog* 9:e1003344.
87. Tonkin CJ, Van Dooren GG, Spurck TP, Struck NS, Good RT, Handman E, Cowman AF, McFadden GI. 2004. Localization of organellar proteins in *Plasmodium falciparum* using a novel set of transfection vectors and a new immunofluorescence fixation method. *Mol Biochem Parasitol* 137:13–21.
88. Blackman MJ, Whittle H, Holder AA. 1991. Processing of the *Plasmodium falciparum* major merozoite surface protein-1: identification of a 33-kilodalton secondary processing product which is shed prior to erythrocyte invasion. *Mol Biochem Parasitol* 49:35–44.
89. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image analysis. *Nat Methods* 9:676–682.
90. Mesén-Ramírez P, Reinsch F, Blancke Soares A, Bergmann B, Ullrich AK, Tenzer S, Spielmann T. 2016. Stable Translocation Intermediates Jam Global Protein Export in *Plasmodium falciparum* Parasites and Link the PTEX Component EXP2 with Translocation Activity. *PLoS Pathog* 12:e1005618.
91. Malleret B, Claser C, Ong ASM, Suwanarusk R, Sriprawat K, Howland SW, Russell B, Nosten F, Rénia L. 2011. A rapid and robust tri-color flow cytometry assay for monitoring malaria parasite development. *Sci Rep* 1:118.
92. Wichers JS, van Gelder C, Fuchs G, Ruge JM, Pietsch E, Ferreira JL, Safavi S, von Thien H, Burda P-C, Mesén-Ramírez P, Spielmann T, Strauss J, Gilberger T-W, Bachmann A. 2021. Characterization of Apicomplexan Amino Acid Transporters (ApiATs) in the Malaria Parasite *Plasmodium falciparum*. *mSphere* <https://doi.org/10.1128/mSphere.00743-21>.
93. Galen SC, Borner J, Martinsen ES, Schaer J, Austin CC, West CJ, Perkins SL. 2018. The polyphyly of *Plasmodium*: Comprehensive phylogenetic analyses of the malaria parasites (Order Haemosporida) reveal widespread taxonomic conflict. *R Soc Open Sci* 5.
94. Yu G, Smith DK, Zhu H, Guan Y, Lam TT-Y. 2017. ggtree : an r package for visualization and annotation of phylogenetic trees with their covariates and other associated data. *Methods Ecol Evol* 8:28–36.
95. Yu G. 2020. Using ggtree to Visualize Data on Tree-Like Structures. *Curr Protoc Bioinforma* 69:e96.

96. Katoh K, Standley DM. 2013. MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability. *Mol Biol Evol* 30:772–780.
97. Madeira F, Park YM, Lee J, Buso N, Gur T, Madhusoodanan N, Basutkar P, Tivey ARN, Potter SC, Finn RD, Lopez R. 2019. The EMBL-EBI search and sequence analysis tools APIs in 2019. *Nucleic Acids Res* 47:W636–W641.
98. R Core Team. 2017. R: A language and environment for statistical computing. R Found Stat Comput Vienna, Austria.
99. Wickham H. 2016. Ggplot2 : elegant graphics for data analysis. Springer.
100. Lin Pedersen T. 2020. patchwork, The Composer of Plots.
101. Lord SJ, Velle KB, Mullins RD, Fritz-Laylin LK. 2020. SuperPlots: Communicating reproducibility and variability in cell biology. *J Cell Biol* 219.
102. Tibúrcio M, Hitz E, Niederwieser I, Kelly G, Davies H, Doerig C, Billker O, Voss TS, Treeck M. 2021. A 39-Amino-Acid C-Terminal Truncation of GDV1 Disrupts Sexual Commitment in *Plasmodium falciparum*. *mSphere* 6.
103. Eksi S, Morahan BJ, Haile Y, Furuya T, Jiang H, Ali O, Xu H, Kiattibutr K, Suri A, Czesny B, Adeyemo A, Myers TG, Sattabongkot J, Su X zhuan, Williamson KC. 2012. *Plasmodium falciparum* Gametocyte Development 1 (Pfgdv1) and Gametocytogenesis Early Gene Identification and Commitment to Sexual Development. *PLoS Pathog* 8.
104. Omasits U, Ahrens CH, Müller S, Wollscheid B. 2014. Protter: Interactive protein feature visualization and integration with experimental proteomic data. *Bioinformatics* 30:884–886.

Table S1: Oligonucleotides (**A**) and plasmids (**B**) used in this study.

A

inter nal #	Target or Primer name	Sequence	Purpose
284	PF3D7_071 6900 rv	GGGacgcgtTAACATCAATTTTGCTTTTGGG	cloning GFP-glmS
285	PF3D7_071 6900 fw	GGGgcgccgctaaGGGTGTGGTAATTCAAGTACG	
280	PF3D7_052 3800 rv	GGGacgcgtATTTGTTGAATATAATTTTTTTAATTG	
281	PF3D7_052 3800 fw	GGGgcgccgctaaGTTTTCTTGTGTTAGCTG	
282	PF3D7_060 9100 rv	GGGacgcgtATGATTATGACCATGATCATGATC	
283	PF3D7_060 9100 fw	GGGgcgccgctaaGGATAGCAGGTGTACGGTTTCTTATC	
288	PF3D7_144 0800 rv	GGGacgcgtATTAGTAATAGAATTTTCATCTTG	
289	PF3D7_144 0800 fw	GGGgcgccgctaaCATTTGCTTCAAATTTGATGAG	
290	Pf3D7_1135 300 rv	GGGacgcgtAGAAGTTTTTGGGGCATATTTCTTTG	
338	Pf3D7_0715 900 (11)	GGGgcgccgctaaCTGGAAATAAATAGATGGAACGTCTTG	
339	Pf3D7_0715 900 (11)	GGGacgcgtAGTATCCCCCTTCAATGTGGAAC	

291	Pf3D7_1135 300 fw	GGGgcgccgctaaGTTATATTATAAAAGGATGATTGG	
315	PF3D7_052 3800 (1) TGD fw	GCGGCCGCTAAAGGAGCACTAAAGGCCAAAGGAAGT	cloning TGD
316	PF3D7_052 3800 (1) TGD rv	acgcgtAATAATGTCATCCTTTTCATTATTAATATT	
317	PF3D7_060 9100 (2) TGD fw	GCGGCCGCTAAGATTTGTTATTTGCAAAAATAATTTGTATT	
318	PF3D7_060 9100 (2) TGD rv	acgcgtATGTctataaaaaataaatcacatac	
319	PF3D7_071 6900 (3) TGD fw	GCGGCCGCTAAAAAATGAAATTATATTTGTACGACATTC	
320	PF3D7_071 6900 (3) TGD rv	acgcgtGGCAATACCAAAGGTAATTAATAAAATTCC	
323	PF3D7_144 0800 (5) TGD fw	GCGGCCGCTAAACAATGTTTAAGGATGATGAAAATAATTTT	
324	PF3D7_144 0800 (5) TGD rv	acgcgtTGTTATTAACAACAATAAATACAGAACT	
	Pf3D7_0715 900 SLI-Tdg F	GGTGCGGCCGCGTGGATAAGATGTCGCGTTTG	
	Pf3D7_0715 900 SLI-Tdg R	GGTACGCGTGTGCTACATTTTTATCATCTTCCTC	
	PF3D7_113 5300 – fw NotI TGD	CTCGcgccgctaaAAAAGTATGATCTCTGGAATATCCAG	cloning 1135300 loxP
	PF3D7_113 5300 – rv MluI TGD	TCCTacgcgtATTTATAAAGAGATCTGTTTTATTATC	
	PF3D7_113 5300 fw NotI loxP	CTCGGCGGCCGCCCGGTAAATCTCTGGAATATCCAGCAAATTG	
	PF3D7_113 5300 rv SpeI loxP:	TCCTACTAGTATTTATAAAGAGATCTGTTTTATTATC	
	PF3D7_113 5300 fw AvrII loxP:	CTCGCCTAGGATGAAGTCAATGATAAGCGGTATTAG	integration check PCR
	PF3D7_113 5300 rv XmaI loxP:	TCCTCCCGGGCTTGTCTTAGGTGCGTACTTTTTAC	
294	PF3D7_060 9100 int_fw	GGTAGTAACAACCTTTGGTTGTTTTATTCC	
295	PF3D7_060 9100 int_rv	tatgtggaaggtaataaatggacaagg	
296	PF3D7_071 6900 int_fw	GAAATTATATTTGTACGACATTCATACTA	
298	PF3D7_144 0800 int_fw	GCACAGAACATTTAAGAAGCAATGATTTTA	
299	PF3D7_144 0800 int_rv	caactgactagccaaaatgttggtctgg	
300	PF3D7_113 5300 int_fw	GATCTCTGGAATATCCAGCAAATTGTTG	
302	PF3D7_071 6900 int_rv	atatttattttgaaccgataagctag	
305	PF3D7_113 5300 int_rv	gccatatattatatacatataaataaagac	
308	PF3D7_052 3800 int_fw	GGCCAAAGGAAGTTGGCTAACGGGGTGGTAG	
309	PF3D7_052 3800 int_rv	gtgtcattcattacctttgaatgg	
369	TGD (PF3D7_060 9100) int check fw	atatatgttttaagctcaaatg	
370	TGD (PF3D7_060	gaggagaagcaaaaacgaaagtaac	

	9100) int check rv		
392	TGD (Pf3D7_071 5900) int check fw	CCCACCGAAATGAACTCTTCGTTGC	
393	TGD (Pf3D7_071 5900) int check rv	CTTTACCTTTAGAGGAGGAATTATTAG	
394	SLI TGD it fw Adelaide	gtggaattgtgagcggataac	
327	Pf3D7_1135 300 compl	ctcgagATGAAGTCAATGATAAGCGG	
328	Pf3D7_1135 300 compl	cctaggGCTTGCTTAGGTGCGTACT	
553	PKNH_0933 400 fw 553	GGGctcgagATGAAGGGAACGTACGTAG	
554	PKNH_0933 400 rv 554	GGGcctaggCACCGCCTTCGAGGCGTAC	
555	PVP01_093 6100 fw 555	GGGctcgagATGAAGGGAACGTACGTACG	
556	PVP01_093 6100 rv 556	GGGcctaggCACCGCCTTCGAGGCGTAC	
p37	Pf3D7_1135 300 fw 5' (TKo)	GATTTTGATATATGATTATAGGATAG	
	Neo 40 rv	CGAATAGCCTCTCCACCCAAG	
	Pf3D7_1135 300 fw NotI	CTCGgcgccgctaaTTATTATAAATCATATAATAAAATAAATG	
	Pf3D7_1135 300 rv AvrII	TCCTcctaggAGAAGTTTTGGGGCATATTTCTTTG	
443	Pf3D7_0715 900 (11) KpnI	GggtaccAGTATCCCCTTTCAATGTGGAAC	
	PF3D MutOut F	GGAAATGCGGCCGCGTTACTTAAGGACGACAAAATATTCA	
	PF3D MutOut R	TAAGTAACGCGGCCGCATTTCCCTTTATATTGTATTGTGCTATTGCGTTCTGTG AAAGACTAACGTACTTGTGTTG	
	PF3D MutIn qcF	tCAAGCAGCctttGCTATGGCAttcctattttctacataaagatggga	
	PF3D MutIn qcR	CATAGCaaagGCTGCTTGaatcGCgaagtaagaacaacgaactcta	
	Pf3D7_1135 300 BamH I fw	cgggatccaccatgaagtcaatgataagcggat	
	Pf3D7_1135 300 XhoI rv	CCGctcgagaccgtgtcttagtgcg	

cloning
complement
ation
constrcuts

excision
PCR primer

cloning
1135300-
2xFKBP-
GFP

cloning
0715900-
3xHA

cloning of
MutIn and
MutOut

cloning
1135300-
YFP

1232

1233 **B**

pSLI- <i>Pf</i> FVRT1-GFP-glmS	this study
pSLI- <i>Pf</i> ZIP1-GFP-glmS	this study
pSLI- <i>Pf</i> CDF-GFP-glmS	this study
pSLI- <i>Pf</i> DMT2-GFP-glmS	this study
pSLI- <i>Pf</i> MFS6-GFP-glmS	this study
pSLI- <i>Pf</i> PMRT1-GFP-glmS	this study
pSLI- <i>Pf</i> FVRT1-GFP-TGD	this study
pSLI- <i>Pf</i> ZIP1-GFP-TGD	this study
pSLI- <i>Pf</i> CDF-GFP-TGD	this study
pSLI- <i>Pf</i> DMT2-GFP-TGD	this study
pSLI- <i>Pf</i> MFS6-GFP-TGD	this study

pSLI- <i>PfPMRT1</i> -GFP-TGD	this study
pSLI- <i>PfCDF</i> -3xHA	this study
pSLI- <i>PfPMRT1</i> -2xFKBP-GFP	this study
P40PX-mCherry	Jonscher et al. 2018 (40)
pLyn-FRB-mCherry	Birnbaum et al. 2017 (37)
pACP-mCherry	Birnbaum et al. 2020 (42)
pARL- <i>ama1</i> ARO-mCherry	Cabrera et al. 2012 (44)
pARL- <i>ama1</i> AMA1-mCherry	Wichers et al. 2021 (47)
pSLI- <i>PfPMRT1</i> -loxP	this study
pARL- <i>nmd3</i> <i>PfPMRT1</i> -ty1	this study
pARL- <i>sf3a2</i> <i>PfPMRT1</i> -ty1	this study
pHcamGDV1-GFP-DD-yDHODH	this study
pSkip-Flox	Birnbaum et al. 2017 (37)
pARL- <i>nmd3</i> <i>PfPMRT1</i> -MutPV-ty1	this study
pARL- <i>nmd3</i> <i>PfPMRT1</i> -MutPC-ty1	this study
pARL- <i>nmd3</i> <i>PvPMRT1</i> -ty1	this study
pARL- <i>nmd3</i> <i>PkPMRT1</i> -ty1	this study
pGEM- <i>PfPMRT1</i> -eYFP	this study
pGEM- <i>PfPMRT1</i> -MutPV-eYFP	this study
pGEM- <i>PfPMRT1</i> -MutPC-eYFP	this study
pGEM-SthK-eYFP	this study

1234

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure S1

A

B

	hit no.	PDB-chain	Z	msd	lali	nres	%id	PDB description on www.rcsb.org
PfFVRT1	1	6c3i-A	45.9	2.0	379	386	21	Crystal structure of the Deinococcus radiodurans Nramp/MntH divalent transition metal transporter G45R mutant in an inward occluded state
	2	5m94-A	39.9	2.6	377	401	24	Crystal structure of Staphylococcus capitis divalent metal ion transporter (DMT) in complex with nanobody
	3	6it2-A	38.9	2.8	440	494	21	Crystal structure of Eremococcus coleocola manganese transporter in complex with an aromatic bis-isothiourea substituted compound
	4	6s3k-A	25.1	3.8	357	573	8	KimA from Bacillus subtilis in inward-facing, occluded state (APC Family Pemease)
	5	6cse-C	24.7	3.4	344	428	13	Crystal structure of sodium/alanine symporter AgcS with L-alanine bound
PfZIP1	1	6pgi-A	16.1	3.6	206	230	15	Asymmetric functions of a binuclear metal cluster within the transport pathway of the ZIP transition metal transporters
	2	7c76-B	9.5	3.5	150	483	5	Cryo-EM structure of human TLR3 in complex with UNC93B1
	3	6m2l-A	9.0	3.6	154	447	6	Crystal structure of Plasmodium falciparum hexose transporter PfHT1 bound with C3361
	4	4gbz-A	8.9	3.6	159	475	7	The structure of the MFS (major facilitator superfamily) proton:xylose symporter XylE bound to D-glucose
	5	6ob6-B	8.8	3.6	155	357	12	Human equilibrative nucleoside transporter-1, S-(4-nitrobenzyl)-6-thioinosine bound, merohedrally twinned
PfCDF	1	6xpd-B	27.1	2.0	300	303	34	Cryo-EM structure of human ZnT8 double mutant - D110N and D224N, determined in outward-facing conformation
	2	3h90-C	18.4	2.8	268	283	15	Structural basis for the autoregulation of the zinc transporter YifP
	3	6vd9-A	12.5	1.4	71	73	32	Metal-bound C-terminal domain of the CzcD transporter from Cupriavidus metallidurans
	4	6vd8-B	12.3	1.3	76	78	37	Metal-bound C-terminal domain of CzcD transporter from Pseudomonas aeruginosa
	5	3w62-A	10.3	2.0	73	79	14	MamM-CTD E289A
PfDMT2	1	6ukj-A	26.0	3.4	291	350	13	Single-Particle Cryo-EM Structure of Plasmodium falciparum Chloroquine Resistance Transporter (PfCRT) 7G8 Isoform
	2	5ogk-E	24.9	3.6	285	298	14	Crystal structure of a nucleotide sugar transporter with bound nucleotide sugar
	3	6xbo-A	24.6	3.8	275	319	12	X-ray crystal structure of the mouse CMP-Sialic acid transporter in complex with 5-methyl CMP
	4	5i20-D	24.0	3.1	272	280	9	Crystal structure of protein (drug metabolite transporter YddG)
	5	5y78-A	23.9	4.0	288	305	14	Crystal structure of the triose-phosphate/phosphate translocator in complex with inorganic phosphate
PfMFS6	1	6t1z-A	36.6	3.0	366	393	15	LmrP from L. lactis, in an outward-open conformation, bound to Hoechst 33342
	2	6s4m-A	36.1	2.3	356	426	17	Crystal structure of the human organic anion transporter MFSD10 (TETTRAN)
	3	3wdo-A	35.7	3.1	364	453	12	Structure of E. coli YajR transporter
	4	3o7p-A	35.2	3.0	356	410	11	Crystal structure of the E.coli Fucose:proton symporter, FucP (N162A)
	5	7ckr-A	35.0	2.7	365	382	7	Cryo-EM structure of the human MCT1/Basigin-2 complex in the presence of anti-cancer drug candidate BAY-8002 in the outward-open conformation
PfPMRT1	1	6z0c-A	15.5	3.3	169	199	4	Structure of in silico modelled artificial Maquette-3 protein
	2	5vj1-A	14.9	3.3	171	196	3	De Novo Photosynthetic Reaction Center Protein Equipped with Heme B and Zn(II) cations
	3	7p5c-B	12.7	3.2	153	392	4	Cryo-EM structure of human TTYH3 in Ca2+ and GDN (Protein Tweety Homolog 3)
	4	6nfm-E	12.5	2.0	116	117	0	Architecture and subunit arrangement of native AMPA receptors (Glutamate-gated AMPA receptor)
	5	6y90-A	12.0	3.5	140	172	8	Structure of full-length CD20 in complex with Rituximab Fab (B-Lymphocyte Antigen CD20)

Dali Z score: significance estimate

msd: difference between the Dali Z value associated with a protein structure pair and the msd value that would have been observed in the case that the two structures had the same crystallographic resolution

lali: number of aligned positions

nres: number of residues in the matched structure

%id: the percentage sequence identity in the match

msd: root-mean-square-deviation over aligned α -carbon position

Figure S2

Figure S3

A

B

C

Figure S4

Figure S5

Figure S6

Figure S7

Figure S8

Figure S9